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Abstract

Molecular biomarkers are chemical signatures that all cell types possess. They are
used in medicine to evaluate both normal biological events and pathogenic
processes. A series of biomarkers associated with cancer of the breast, ovaries and
other parts of the female reproductive tract and the monitoring of pregnancy were
measured in disease‐free women. The biomarkers measured were prostate specific
antigen (PSA), CA125, CA15‐3, CA72‐4, and pregnancy associated plasma protein‐a
(PAPP‐A). The patterns of change during natural and stimulated ovarian cycles and
early pregnancy were investigated to determine if these biomarkers could reflect
normal events relating to ovulation and implantation/placentation. In addition, the
study was able to investigate the possible erroneous crossing of clinical cut‐off
values associated with disease due to other biological processes rather than the
disease itself.

A total of 73 blood samples (10 women) taken throughout the natural menstrual
cycle, 64 blood samples (11 women) during stimulated ovarian cycles and 86
blood samples (14 women) during early pregnancy monitoring were collected and
all samples were analysed by batch analysis on the Roche Cobas e411.
Concentrations of CA125, tPSA, CA15‐3 and CA72‐4 showed no significant
difference between the natural and stimulated ovarian cycle groups (p≥0.5989).
On average the mean PAPP‐A of the natural group was 2.41±0.58 mIU/L higher
than the stimulated group (t = 4.10, p < 0.001). CA125 and CA15‐3 results were
both significantly influenced by the stage of the cycle (p=<0.0001), whereas tPSA
and PAPP‐A concentrations revealed no significant changes (p≥0.65). In early
pregnancy, concentrations of tPSA (in the 9/14 (64%) women with detectable
levels) and PAPP‐A increased steadily from 4 weeks to 7 weeks (p<0.01). There
was a significant effect of the stage of gestation (p=0.0012) on CA125
concentration with peak levels occurring at 5.5 weeks (57.98±27.45U/mL) before
reducing again by week 7. The concentration of CA15‐3 reduced as the pregnancy
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progressed (p<0.0001). The CA72‐4 concentration in pregnancy was on average
2.11±0.38U/ml.

In conclusion, batch analysis of all samples from each of the participants was
conducted to maximise the possibility that any changes seen in biomarker
concentrations were due to biological fluctuations and not because of assay
variability. Ovarian stimulation reduced serum PAPP‐A levels, whilst CA125 and
CA15‐3 were unaffected by ovarian stimulation per se but showed cyclical changes
throughout both natural and stimulated cycles. PAPP‐A, CA125, tPSA and CA15‐3
all showed consistent changes in early pregnancy, and their combined benefits as
markers of different aspects of implantation, embryogenesis and placentation
warrants further investigation. Only CA125 in early pregnancy crossed the cut‐off
associated with disease, ie ovarian cancer, and other gynaecological and
inflammatory conditions. Care must therefore be taken when using CA125
determinations to detect disease if the woman is less than 7 weeks pregnant as
transient elevations during this time appear normal.
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Introduction

In 1998, the National Institutes of Health Biomarkers Definitions Working Group
defined a biomarker as “a characteristic that is objectively measured and evaluated
as an indicator of normal biological processes, pathogenic processes, or
pharmacologic responses to a therapeutic intervention” (Strimbu & Tavel, 2010).
However, many biomarkers of disease are often present in healthy unaffected
people too, albeit at low concentrations and so there needs to be certainty that
raised levels of such biomarkers do not occur during normal periods of increased
cellular growth. A series of biomarkers associated with cancer of the breast,
ovaries and other parts of the female reproductive tract were measured in healthy
women on the basis that the concentration of these may be more likely to be
affected by the reproductive status of the women. The biomarkers measured in the
present study were prostate specific antigen (tPSA), CA125, CA15‐3, CA72‐4 and
pregnancy associated plasma protein‐a (PAPP‐A). The patterns of change
throughout natural and stimulated ovarian cycles and in early pregnancy were
investigated to determine if these biomarkers could reflect normal events relating
to ovulation and implantation/placentation. In addition, the study was able to
investigate the possible erroneous crossing of clinical cut‐off values associated
with disease due to other biological processes rather than the disease itself.

1.1 The Female Reproductive System
1.1.1 The Female Reproductive Cycle
Throughout a female’s reproductive years her ovaries and uterus go through
monthly cyclical changes which respectively involve developing gametes
through oogenesis in the ovaries and preparing the uterus for possible
implantation of an embryo (Oktem & Oktay, 2008). The ovaries, the
hypothalamus and the anterior pituitary are all involved in secreting
hormones which control the phases of the cycle. The term used to describe
the formation of gametes in the ovaries is oogenesis. Oogenesis begins early
during foetal development, starting when the primordial follicles begin
1

migrating from the yolk sac into the ovaries where they differentiate into
oogonia. Oogonia are diploid with the full 46 chromosomes and undergo
mitosis to produce millions of germ cells. Most of the germ cells degenerate
through atresia, however, some will form primary oocytes which enter
prophase I of meiosis and remain there until puberty (Verlhac & Villeneuve,
2010). The primary oocyte is surrounded by a flattened layer of follicular
cells and is now called a primordial follicle. At birth, a female will have
anywhere between 200,000 – 2,000,000 primary oocytes; at puberty there
are approximately 400,000 remaining. In the average female, only 400
primary oocytes mature and ovulate (Tortora & Derrickson, 2010). At the
permanent cessation of the menstrual cycle, a woman is said to have reached
menopause, where approximately 1000 follicles are left in each ovary (Oktem
& Oktay, 2008).

The onset of menstrual cycling is termed menarche. Young women who have
begun menarche will not usually have their first ovulation until around 6 or
more months after commencement and the menstrual cycles often do not
become regular until years later (Beckman & Feuston, 2003). The
proliferative phase of the uterine cycle, in concert with the ovarian cycle,
involves building up the stratum functionalis of the endometrium of the
uterus in the first two weeks of the cycle (stimulated by oestrogen from the
developing follicles in the ovaries). Following the LH surge, progesterone is
secreted (at the expense of oestrogen) as the follicle becomes luteinised an in
response the endometrium undergoes secretory changes. If fertilization does
not occur, progesterone levels (produced by the remnants of the follicle that
ovulated, the corpus luteum) drop off which causes the stratum functionalis
to slough away in a menstrual bleed (M. Johnson, 2013).

Gonadotrophin‐releasing hormone (GnRH) is a hormone secreted by the
hypothalamus that stimulates the anterior pituitary to release luteinizing
hormone (LH) and follicle‐stimulating hormone (FSH) (Richards & Pangas,
2

2010). FSH initiates follicular growth, and LH stimulates the ovarian follicles
to keep developing. Just before mid‐cycle there are many cumulative GnRH
pulses, which stimulate the concentration of LH to surge, initiating ovulation
and then the formation of the corpus luteum. From the follicle remnants, the
corpus luteum is responsible for producing oestrogen, progesterone, relaxin
and inhibin (Tortora & Derrickson, 2010). The oestrogen that is secreted by
the ovarian follicles is important for maintaining the female reproductive
organs and secondary sex characteristics, amongst other specialised
functions. Progesterone is secreted mainly from the corpus luteum and its
function is to work with the oestrogen to prepare the endometrium for
implantation (and maintain it) as well as preparing the mammary glands for
milk production (Tortora & Derrickson, 2010).

1.1.2 Phases of the Female Reproductive Cycle
The typical duration of the female reproductive cycle is between 24 and 36
days, however most texts refer to the cycle as being 28 days, comprising four
phases (Tortora & Derrickson, 2010). The menstrual phase is the first 5 days
of the cycle and this is where the ovaries, under the influence of FSH, develop
several of the primordial follicles into primary and secondary follicles.
Development of the follicles can take several months which means that the
follicles that have just begun their maturation process won’t be ovulated until
some months later (Tortora & Derrickson, 2010). During this (menstrual)
phase the oestrogen and progesterone levels decrease, stimulating the
release of prostaglandins which causes the uterine arterioles to constrict. The
constriction of the arterioles deprives the cells of the stratum functionalis of
oxygen, killing the cells so that they eventually slough off. The mix of blood,
mucus, epithelial cells and tissue fluid from the endometrium flow from the
uterus through the cervix and out of the vagina to the exterior as menses (M.
H. Johnson & Everitt, 2007).
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Next in the cycle is the preovulatory phase. This is the time between the end
of the menstrual phase and ovulation. In a 28 day cycle it is recognised as
lasting from day 6 to day 13, however in most women this length varies
greatly which is the main contributor to the different cycle lengths between
women (M. H. Johnson & Everitt, 2007). It is during this phase that some of
the secondary follicles start producing oestrogen’s (mainly 17β‐oestradiol)
and inhibin‐A. It is also around this time that one of the secondary follicles
(the dominant follicle) begins to outgrow the others and produces most of
the oestrogens and inhibin‐A (M. H. Johnson & Everitt, 2007). The oestrogen’s
and inhibin down regulate the production of FSH via a negative feedback
mechanism operating through the hypothalamus and pituitary gland which
causes all of the smaller follicles to stop developing and undergo atresia. It is
the dominant follicle that develops into a mature Graafian follicle and it will
continue to grow until it reaches between 18‐22mm in diameter, forming a
bulging cyst on the surface of the ovary (M. H. Johnson & Everitt, 2007).
Paralleling the developing follicles in the ovaries, the increase in oestrogen is
helping to build the endometrial lining of the uterus by stimulating the cells
of the stratum basalis to undergo mitosis and form a new stratum
functionalis (Tortora & Derrickson, 2010).

Ovulation in a 28 day cycle happens on day 14. The increase in oestrogen
from the follicles stimulates the hypothalamus to release GnRH and the
anterior pituitary to secrete LH via a positive feedback mechanism (Tortora
& Derrickson, 2010). The surge of LH causes the Graafian follicle to rupture,
expelling the secondary oocyte into the pelvic cavity where it is wafted up
into the fallopian tube by the fimbriae (M. H. Johnson & Everitt, 2007).

The next phase of the female reproductive cycle is the postovulatory phase.
In a 28 day cycle this phase begins on day 15 and lasts until the next
menstrual cycle at day 28. Once the Graafian follicle expels its contents the
follicle collapses and a clot is formed over the rupture site. Under the
4

influence of LH, the granulosa and theca interna cells combine and form the
corpus luteum (Tortora & Derrickson, 2010). The corpus luteum begins
secreting oestrogens, progesterone, inhibin and relaxin. If the oocyte is not
fertilized the corpus luteum survives just 2 weeks before degenerating into a
corpus albicans (Tortora & Derrickson, 2010). The oestrogens, progesterone,
inhibin and relaxin levels decrease and so the levels of LH, FSH and GnRH
begin to rise to start a new reproductive cycle. Thus, a woman’s fertility is
dependent upon these specific endocrine events occurring in the described
succinct order (Richards & Pangas, 2010).

1.1.3 Female Hormones and Pregnancy
If the ovulated oocyte is fertilized and the cell starts to divide, the corpus
luteum survives past the two weeks with the aid of the hormone human
chorionic gonadotrophin (hCG). This hormone is specifically produced by the
chorion of the developing embryo from 8 days post‐fertilization (Tortora &
Derrickson, 2010). The hCG acts similarly to LH as it stimulates the secretory
actions of the corpus luteum. The progesterone and oestrogen secreted by
the corpus luteum encourages the coiling and growth of endometrial glands
along with thickening and vascularisation of the endometrium (Tortora &
Derrickson, 2010). The body prepares for the implantation of the embryo,
however if this does not occur, the body will undergo menstruation because
the progesterone and oestrogen levels decrease as the corpus luteum
undergoes luteolysis due to absence of HCG which acts as a sustaining
hormone (M. H. Johnson & Everitt, 2007).

If the embryo implants into the endometrium of the uterus, the corpus
luteum and the ovaries will continue to secrete progesterone and oestrogens
during the first three to four months of pregnancy (M. Johnson, 2013). The
hormone levels in this period aren’t much greater than at ovulation; however
from the third month onwards the placenta starts producing the oestrogens
and progesterone at higher levels which maintains the pregnancy (M.
5

Johnson, 2013; O'Leary, Boyne, Flett, Beilby, & James, 1991). The level of hCG
peaks around week 9 of pregnancy and thereafter it declines until birth
(Tortora & Derrickson, 2010).

1.2 Infertility in Humans
Infertility in humans is defined as the inability to achieve pregnancy within one
year after having regular, unprotected sexual intercourse (Evers, 2002). Ogawa
et al (2011) states that infertility affects approximately 10% of all couples in
developed countries. Hull et al. (1985) describe reasons for infertility along with
the approximate frequency of each, which shows that around 15% of couples
will have more than one cause of infertility. Dysfunction in the production or
function of sperm accounts for around 30% of infertility cases, which is the
largest scoring of the categories. Ovulation failure and unexplained infertility
both contribute 25% of infertility cases, tubal infective damage accounts for
20%, endometriosis and coital failure or infrequency account for 5% each,
cervical mucus defect is 3% and uterine abnormalities <1% (Mitwally & Casper,
2003). A World Health Organization report stated that in 2003 there were more
than 186 million couples in developing countries that were affected by
infertility (World Health Organization, 2003). It was highlighted that most of
this was attributable to the high prevalence of infectious diseases such as
chlamydia and gonorrhoea which are linked with infertility (World Health
Organization, 2003). Assisted reproductive technology (ART) can help treat
infertile couples unable to conceive naturally. ART has reasonably high
pregnancy rates however, it is also associated with the risk of multiple
pregnancies and ovarian hyperstimulation syndrome (Van Voorhis, 2006).
Advances in medical research have broadened our understanding of why
couples are infertile. This has led to the development of a range of diagnostic
tools and thus treatment options for the infertile couple. However, Cahill et al
(2002), states that in approximately 25% of couples, after a full investigation,
the cause for their infertility will not be found.
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1.3 Assisted Reproductive Technology (ART)
1.3.1 Introduction
Assisted reproductive technology (ART) is the term used worldwide to
describe all treatments or procedures that involve the in vitro handling of
human oocytes, sperm and human embryos with the intention of achieving a
pregnancy (Zegers‐Hochshild et al., 2009). The goal of assisted reproductive
technology is to assist subfertile women in becoming pregnant if they have
been unsuccessful in achieving pregnancy naturally. The procedures outlined
in the International Committee for Monitoring Assisted Reproductive
Technology (ICMART) glossary that came under the heading of assisted
reproductive technologies were; in vitro fertilization (IVF), intracytoplasmic
sperm injection (ICSI), embryo transfer (ET), zygote intrafallopian transfer
(ZIFT), gamete intrafallopian transfer (GIFT), gamete and embryo
cryopreservation, tubal embryo transfer, gestational surrogacy along with
sperm, oocyte and embryo donation (Zegers‐Hochshild et al., 2009).

Anderson et al. (2008) described that in Europe, more than 367,000 assisted
reproductive technology cycles were performed in more than 1000 clinics
over 29 countries in the year 2004. Annually Europe alone generates over
85,000 clinical pregnancies from ART treatments with a pregnancy rate of
28% per transfer in 2004 (Andersen et al., 2008). In the United States of
America, over 100,000 assisted reproductive technology cycles are
performed each year which results in around 35,000 pregnancies (Society for
Assisted Reproductive Technology & American Society for Reproductive
Medicine, 2007).

1.3.2 Controlled Ovarian Hyperstimulation
Controlled ovarian hyperstimulation is a treatment where the ovaries are
stimulated to produce multiple mature follicles for use with ART treatments
such as IVF or ICSI (Mitwally & Casper, 2003). This form of controlled ovarian
hyperstimulation is different to ovulation induction treatment because the
7

aim of this treatment is to produce multiple large follicles, compared with
ovulation induction where multiple follicles are not the desired outcome. The
two most frequently used medications in ovarian stimulation are;
Clomiphene citrate and an injectable form of gonadotrophin such as follicle
stimulating hormone (FSH) (Guzick, Carson, & Coutifaris, 1999). Daily doses
of FSH ranging from 150‐225IU result in a greater yield of follicles and
therefore a greater number of oocytes for collection (Fauser & Van Heusden,
1997). The main guideline for ovarian stimulation is to maximise the
beneficial outcome of the treatment; high oocyte yield, whilst minimizing the
risk of over stimulating the ovaries or creating a multiple pregnancy. For
these reasons close monitoring and adjustments are required based on
individual outcomes (Fauser, 2008).

Signs of a diminishing ovarian reserve in females include; an elevated basal
FSH level, being over the age of 40 years and having and antral follicle count
(AFC) of fewer than five follicles sized between 2‐10mm prior to treatment
and a reduced anti‐mullerian hormone (AMH) (Klinkert, Broekmans,
Looman, Habbema, & Te Velde, 2005; Klinkert, Broekmans, Looman, & Te
Velde, 2004). Klinkert et al. (2004) also explains that it would be unusual for
a patient with normal signs of ovarian reserve to have a poor response to
gonadotrophin stimulation.

1.3.3 IVF/ICSI
In vitro fertilization (IVF) is a procedure that involves extracting an oocyte
from un‐ovulated follicle in the ovary and fertilizing it with spermatozoa,
outside of the body in the laboratory (Zegers‐Hochshild et al., 2009). IVF can
be performed on oocytes collected after the natural maturation of follicles in
the ovary or after the controlled ovarian hyperstimulation mentioned
previously. The difference in outcome is the yield of follicles collected for
fertilization. The biological age of a woman will affect her chances of
conceiving with IVF treatment. A study conducted in the UK showed that the
8

pregnancy rate for single embryo transfers in natural IVF cycles was 17% for
women aged <30years, 13% for women aged 31‐35 years and 11% for
women aged 36‐40 years (Healy, Trounson, & Andersen, 1994).

Spermatozoa can fail to fertilize an egg, even when they are placed in close
proximity to an egg in settings such as IVF. This can occur because of
deficiencies in sperm quality or quantity (Gardner, Weissman, Howles, &
Shoham, 2009). Intracytoplasmic sperm injection (ICSI) is a procedure which
involves injecting a single spermatozoon into the cytoplasm of an oocyte,
directly bypassing the zona pellucida and oolemma. This procedure has
allowed for greater fertilization rates because men with deficient numbers of
progressively motile sperm and men who are classed as azoospermic can
have the sperm in the testis and epididymis extracted and injected directly
into the egg (Gardner et al., 2009).

1.4 Biomarkers
A biomarker is defined as “a characteristic that is measured and evaluated as an
indicator

of

normal

biologic

processes,

pathogenic

processes,

or

pharmacological responses to a therapeutic intervention” (Atkinson et al., 2001)
and, as such, biomarkers can include a range of measures from images obtained
by X‐rays to molecular biomarkers that can be measured in blood. Biomarkers
are used in many areas of medicine, for example oncology (Bhatt, Mathur,
Farooque, Verma, & Dwarakanath, 2010), but there is an increased awareness of
the potential benefits of biomarkers when applied to reproductive medicine
(Palmer & Barnhart, 2013).

1.4.1 Tumour markers
Tumour markers are commonly used in the detection and monitoring of
cancer. Cancer is an umbrella term that describes many different diseases, all
of which involve somatic or germinal cells that have alterations in different
9

genes, allowing the cells to resist natural cell death processes, so they
proliferate uncontrollably and indefinitely (Cho, 2007). The American Cancer
Society projected that in 2012 there would be 1,638,910 new cases of cancer
and 577,190 deaths as a results of cancer in the United States (Siegel,
Naishadham, & Jemal, 2012). Using biomarkers to detect diseases such as
cancer plays an important role in medicine, and it is important to define the
exact relationship that the biomarkers have with the actual pathology. Whilst
tumour markers are often the normal endogenous products found in the
plasma and serum of healthy individuals in very small concentrations (Trape,
Molina, & Sant, 2004), these molecules are produced by tumour cells in
greater amounts which can be an indicator of cancer presence (Malati, 2007).
Tumour markers can be expressed in the body’s tissues, present as
intracellular substances, or they might be released into the circulation and
present in the serum (Bates & Longo, 1987; Harnden, 1985; Virji, Mercer, &
Herberman, 1988). The majority of tumour markers are proteins,
glycoproteins, proteoglycans, carbohydrates, glycolipids, enzymes or
hormones (Sarandakou, Protonotariou, & Rizos, 2007; Trape et al., 2011).

When a cell becomes cancerous, the processes of differentiation can result in
the excess synthesis and release of molecules, or the induction of other cells
to synthesize these molecules (Trape et al., 2011). The products that the cells
produce are called tumour markers, and detecting any elevations of tumour
markers is used frequently for the diagnosis of tumours, the prognosis for the
patient, identifying the stage of disease and in monitoring the growth of the
tumour (Malati, 2007). The criteria for the “ideal” tumour marker requires
that it should be sensitive and have low false negatives, be highly specific
with low false positives, the predictive values should be highly positive or
negative and it should have an accuracy of 100% in diagnosing and
differentiating between healthy patients and patients with tumours (Malati,
2007). The ideal tumour marker would show a positive correlation between
the tumour marker and tumour size, predict any early recurrence of tumour
cells, have prognostic ability, and be able to detect early tumours (Bates,
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1991). The ideal tumour marker should be either highly specific to one type
of tumour or a known universal marker for many tumour types, as well as
being straightforward to run as an assay, indicating any changes in the
cancers presence. The reality is that no one tumour marker is specific to any
one malignancy; they are usually only specific to an organ or group of
malignancies (Malati, 2007). The efficacy of a tumour marker to effectively
diagnose disease relies on its positive and negative predictive value. The
positive predictive value shows the probability that the disease the marker is
looking for is actually present if the test shows a positive result. The converse
applies for the negative predictive value, where the test result should be
negative if there is no disease present. The sensitivity of a marker is if a
positive result occurs there will positively be a tumour present and the
specificity of the tumour marker shows how many healthy individuals test
negative for the marker (Malati, 2007).

Tumour markers can in some cases increase in concentration in patients that
are healthy and have no neoplasia, which results in a false positive test result
(Trape et al., 2004). The pathophysiological processes that are responsible
for this increase include cell necrosis or inflammation which may lead to the
release and therefore increase in concentrations of cell products in the
serum, or a dysfunction in the organ that is responsible for eliminating the
molecule resulting in a reduction in the molecule’s catabolism (Trape et al.,
2011). Although there has been a lot of research into cancer biomarkers and
other biomarkers of disease (Palmer & Barnhart, 2013), most of the research
is related to the specificity and sensitivity to the diseases the markers are
associated with, the ability to monitor treatment therapies using biomarkers,
and the strength of biomarkers to give a prognosis for disease (Bates, 1991).
Some of this research has highlighted that these antigens are also present in
varying amounts in the tissues, serum and other biological fluids of healthy
individuals which could be the result of the variation in reproductive
hormones releasing many growth factors and peptides that are used as
tumour markers. This has led to the questioning of what the normal
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fluctuations of these tumour markers are in healthy women throughout the
natural menstrual cycle, stimulated ovarian cycle and early pregnancy
(Palmer & Barnhart, 2013). An understanding of the changes in serum
concentrations of the markers in healthy patients would allow for a more
accurate interpretation of results by clinicians. The tumour markers that
have been explored in this research project include the carbohydrate
antigens CA125, CA15‐3, CA72‐4, and the enzyme prostate specific antigen
(tPSA).

1.4.1.1 Serum CA125
CA125 is a tumour associated antigen which belongs to the family of
hybridoma‐defined tumour markers which is used in the monitoring of
epithelial ovarian carcinoma. CA125 can be detected in the serum and is
found in a large proportion of non‐mucinous ovarian tumours that are of
epithelial origin (McLemore et al., 2012; Schlageter, Cassinat, Toubert,
Borschneck, & Rain, 1998; Toki, Kubota, Lu, & Nakayama, 2000). CA125 is
not present on the surface epithelium of normal foetal and adult ovaries;
however it has been demonstrated in the epithelium of the endometrium,
endocervix and oviduct (Kabawat, Bast, Welch, Knapp, & Colvin, 1983).
CA125 has also been found in amniotic fluid and coelomic epithelium
which are both tissues of foetal origin. Elevated levels of CA125 have also
been

associated

with

benign

gynaecological

diseases

such

as

endometriosis, cervitis, ovarian cysts, ovarian metaplasia, adenomyosis
and myomatous uterus (Toki et al., 2000). Based on a study which used
888 blood donors and 56 healthy participants, the normal value of CA125
in the identification of carcinoma was set at an upper limit of 35U/ml
(Klug, Bast, Niloff, Knapp, & Zurawski, 1984). The highest levels of CA125
are said to occur in patients suffering from ovarian carcinoma, however
research has shown that asymptomatic healthy women can have elevated
levels of CA125 without the presence of disease (Toki et al., 2000). One
study found that in healthy women the mean CA125 concentration is
positively correlated with age where 12.7% of women aged 40‐55 years,
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16% of women aged 56‐70 and 32.3% of women aged over 70 years had
serum concentrations of CA125 over the normal limits (Dehaghani, Ghiam,
Hosseini, Mansouri, & Ghaderi, 2007).

Various authors have suggested that the circulatory CA125 concentration
increases during the menstruation phase of the natural cycle. In a study by
Bon et al. (1999), the CA125 concentration was measured in healthy
women during spontaneous ovulatory cycles. This study confirmed earlier
reports that there was a phase dependent increase in CA125 concentration
during menstruation in women and that there is a negative correlation
between oestradiol and CA125 levels in spontaneous ovulatory cycles
(Haga, Sakamoto, Hiroshi, Yoshimura, & Akagi, 1986; Jager, Meier, Wildt,
Sauerbrei, & Lang, 1988; Pittaway & Fayez, 1987; Touitou, Darbois,
Bogdan, Auzeby, & Keusseoglou, 1989). CA125 was again examined during
the menstrual cycle in apparently healthy women in a more recent study
where the concentration of CA125 over the menstrual cycle was compared
between two different automated analysers, with the conclusion that
CA125 is highest during menses however the changes are not clinically
significant in healthy women (McLemore, 2012). The endometrium has
been shown to be responsible for the cyclical changes of CA125 in the
menstrual cycle however the exact mechanisms that allow the release of
CA125 into the circulation has not yet been explained (Kafali, Artunc, &
Erdem, 2007; Ziemet, Muller‐Holzner, Marth, Daxenbichler, & Dapunt,
1993).

CA125 has been measured throughout ovarian stimulation cycles for ART
treatment showing levels are significantly higher in the luteal phase rather
than during the stimulation phase or at oocyte collection (Zweers, De
Boever, Serreyn, & Vandekerckhove, 1990). It has been postulated that
CA125 may well be a good predictor of pregnancy success for ART
treatments because concentrations on the day of oocyte retrieval
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>10IU/ml had an accuracy of 86.6% for pregnancy, with CA125
concentration being a measure of endometrial receptivity and therefore
predictor of pregnancy success (Tavmergen, Sendag, Goker, & Levi, 2001).
Significant differences in CA125 levels have also been shown between
viable pregnancies and both anembryonic and ectopic pregnancies,
however due to overlaps in the ranges of values for each group the
findings were not of clinical significance (Jacobs et al., 1990).

Many authors have published reports showing that CA125 plasma
concentrations are increased during pregnancy (Aslam, Ong, Woelfer,
Nicolaides, & Jurkovic, 2000; Halila, Stenman, & Seppala, 1986; Kobayashi,
Takashima, ASagawa, Mori, & Fujii, 1993; Niloff, Klug, Schaetzl, Reynolds,
& Bast, 1984). Early reports from Niloff et al. (1984) and Touitou et al.
(1989) showed that 16% and 12.5% respectively of pregnant women in
the first trimester had elevated levels of CA125 and other publications
then advanced this and concluded that 20‐24% of pregnant women,
regardless of gestation, had elevated levels of CA125 (Halila et al., 1986;
Pittaway & Fayez, 1987). The CA125 antigen was then shown to be
expressed during embryonic development where levels of CA125 are
significantly higher in the first and third trimesters of pregnancy (Bon et
al., 2001; Hardardottir et al., 1990). Other studies have shown maternal
CA125 levels to reach an average of 85U/mL in the first trimester and then
drop to the average non‐pregnant levels during the second and third
trimester (Haga et al., 1986; Seki, Kikuchi, & Kato, 1986). This was
supported by a later study which showed peak CA125 levels occurring
between weeks 6‐7 of gestation in naturally conceived pregnancies and
further findings where pregnancies achieved via assisted conception had
levels of at least twice those found in non‐pregnant women (Jacobs et al.,
1990). Research by Ocer, Bese, Saridogan, Aydinli, and Atasii (1992)
suggested that maternal serum CA125 >65U/ml in the first trimester
presented a risk of spontaneous abortion of 83.3% and that in those
pregnancies with bleeding lasting 3 or more days, with elevated CA125
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levels, this risk rose to 100%. A later study found that all of the successful
pregnancies in the study group had CA125 levels <93U/ml between weeks
7‐12 gestation and those that aborted had levels >125U/ml (Azogui,
Yaronovski, Zohar, & Ben‐Shlomo, 1996). Furthermore, one study found
that tubal pregnancies with no uterine bleeding had conversely much
lower CA125 concentrations than intrauterine pregnancies

whereby

levels were within the normal non‐pregnant range of <35U/ml (Kobayashi
et al., 1993).

Some scientists hypothesize that the first trimester increase in CA125 is
the result of decidual CA125 having access to maternal circulation via
tubal reflux because after the fusion of the decidua capsularis and decidua
parietalis which obliterate the endometrium around 10‐12 weeks, tubal
closure follows and then the maternal CA125 levels decrease (Kobayashi
et al., 1993). Other reports suggested that it is the invasion of the
trophoblast in the decidua during placentation that causes the increase in
CA125 in the first trimester and an increase in the third trimester is the
result of the subsequent deplacentation during which decidual CA125 can
gain access to the maternal circulation (Kobayashi, Sagawa, & Nakamura,
1989). When indicated as a predictor of spontaneous abortion, authors
suggest that the elevated CA125 level is an indicator of the decidual
destruction which is associated with pregnancy outcome (Ocer et al.,
1992).

Although it may be argued that CA125 has been investigated extensively in
women, it was important that this project included CA125 so that the
results from this study can be compared to previous research to confirm
that the method being used to measure the compounds is robust and
reproducible for all of the other analytes. This research aims to add to the
current literature using the latest in automated immunoassay technology
and serial sampling of individual women.
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1.4.1.2 Prostate Specific Antigen (PSA)
Prostate specific antigen (PSA) is a serine protease which is produced by
both normal and neoplastic epithelial cells of the prostate. PSA is regulated
by androgens and has been extensively studied as a biomarker for
prostate cancer (Bhatt et al., 2010; Chu, 1997; Luke & Coffery, 1994). It
was first discovered in 1971, and then isolated in 1979 from an extract of
human prostate, however, it wasn’t until 1980 when Papsidero and his
colleagues began measuring PSA quantitatively that its properties for
clinical use as a biomarker for identifying prostate cancer were identified
(Bhatt et al., 2010; Papsidero, Wang, Valenzuela, Murphy, & Chu, 1980; M.
Wang, Valenzuela, Murphy, & Chu, 1979). The epithelium of the prostate
synthesizes PSA and plays the role of effectively preventing the release of
the protease into the circulatory system (Malati, 2007). PSA can leave the
prostate and is often present, normally in small amounts, in the serum of
healthy individuals. The protease can form complexes with many protease
inhibitors in the serum and seminal fluid, giving rise to multiple molecular
forms which circulate through the blood. The major immunoreactive form
of PSA is the 100KD complex PSA‐ACT, which constitutes up to 90% of
total PSA in the serum. There are other complexes, such as PSA‐AT and
PSA‐PCI, which occur at significantly lower concentrations in the serum i.e.
less than 1% of PSA. Finally, PSA can form a complex with alpha‐2
macroglobulin (α2 M) which encapsulates the PSA molecule, masking the
epitopes on the surface of the antigen further preventing its
immunodetection in enzyme immunoassays (Malati, 2007).

PSA levels in the serum are often elevated in men with prostate cancer
which has made it the most clinically significant tumour marker for the
disease (Papsidero et al., 1980). This led to the American Urological
Association (AUA) and the Food and Drug Administration (FDA) in the
United States, originally promoting recommendations that all men over
the age of 50 who have no family history of prostate cancer, and those
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with a family history who are over the age of 40, have annual digital rectal
examinations for prostate abnormalities as well as serum PSA level checks
(Malati, 2007). However, prostate cancer can be present in the body even
when the serum level for PSA is not elevated (Thompson et al., 2004). Due
to this, there have been many calls to stop using PSA as a routine screening
test in men and now it is no longer used in the USA (Friedrich, 2011).

Prostate‐specific antigen has certainly been incorrectly named since
advances in the sensitivity of technology have shown PSA to be expressed
in females (Aksoy, Akcay, Umudum, Yildirim, & Memisogullari, 2002; Giai
et al., 1995). PSA was found to be expressed by normal, hyperplastic and
neoplastic female breast tissue where it is present in 30%‐40% of breast
tumours in females (H. Yu, Diamandis, & Sutherland, 1994; H. Yu et al.,
1995). The PSA concentration does not correlate with the reproductive
hormones LH, FSH and oestradiol, however, it is said to follow the
progesterone concentration peak (N. Zarghami, L. Grass, E. Sauter, & E.
Diamandis, 1997). Steroid hormone receptor‐positive breast carcinoma
cell line T‐47D was used in a tissue culture system which reproduces the
process of PSA production by breast cells to show that only upon
stimulation by steroid hormones does the cell line produce PSA in a dose‐
dependent manner (N. Zarghami et al., 1997). According to one study
investigating women over the age of 50 years, PSA levels are not
significantly different between healthy women and those with breast
cancer (Giai et al., 1995).

Further studies have shown that PSA is produced in a cyclical manner
during the natural menstrual cycle where the peak concentration is during
the mid to late follicular phase and lowest during the mid to late luteal
phase of the cycle (N. Zarghami et al., 1997). These findings have been
confirmed by a later study which showed PSA concentrations in the saliva
of women were increased in the follicular phase and around mid‐cycle
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compared to the luteal and early follicular phases (Aksoy, Akcay, et al.,
2002). Prostate specific antigen concentrations are very low in female
serum and it is not known why some women have measurable levels of
PSA and others do not. Zarghami et al. (1997) suggest that it is because of
an inability of PSA to diffuse out of the breast tissue into the blood
circulation.

Prostate specific antigen was identified in amniotic fluid during pregnancy
where the concentration increased from 11 weeks until 21 weeks of
gestation before it decreased until birth (H. Yu et al., 1995). This study
also found that PSA is in greater concentrations in the serum of pregnant
women compared to non‐pregnant women (H. Yu et al., 1995). The same
group also detected PSA in the breast milk of lactating women, although
concentrations were variable between women and its biological role in
milk is still unknown (H. Yu & Diamandis, 1995). As such, this led the
authors to suggest that as well as serving as a growth factor regulator in
cancer, PSA may play a role in normal foetal development throughout
pregnancy. There are conflicting opinions about PSA and its role in pre‐
natal screening for Down Syndrome. One study conducted in 1998
concluded that the concentration of PSA in Down Syndrome pregnancies
was significantly higher than in normal pregnancies (Lambert‐Messerlian,
Canick, Melegos, & Diamandis, 1998). However, another study from the
same year could not confirm that there was any variation in maternal PSA
concentrations with gestational age nor could they confirm that maternal
PSA levels were increased in pregnancies affected by Down Syndrome
(Spencer & Carpenter, 1998). Another study found PSA in the
endometrium of the uterus and that it may play a role in uterine regulation
(Mannello et al., 1996). Although the physiological role and biological
significance of PSA is still not completely understood it has been
hypothesised as a growth factor regulator which is produced by cells
exhibiting steroid hormone receptors (E. Diamandis & H. Yu, 1995).
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1.4.1.3 Serum CA15‐3
CA15‐3 is a mucin‐like glycoprotein encoded by the gene MUC1 which was
first identified by two monoclonal antibodies 115D8 and DF3 (Kamal et al.,
2011; Schlageter et al., 1998). Mucins provide a protective layer on the
surface of epithelial cells by providing lubrication, preventing dehydration
and protecting against proteolysis due to its high degree of glycosylation
(Al‐Azemi, Refaat, Aplin, & Ledger, 2009). MUC1 is heterogeneously
expressed on the surface of epithelial cells, including those in the breast
and upper reproductive tract and is thought to prevent embryo
implantation (Al‐Azemi et al., 2009). Meseguer et al. (2001), suggesting
that the human blastocyst can produce certain factors that remove MUC1
from a site to facilitate implantation in the endometrium. Expression of
MUC1 has been shown to be progesterone dependent and is up regulated
in endometrial epithelial cells in the luteal phase of the menstrual cycle
(Aplin, Hey, & Graham, 1998; Hey, Graham, Seif, & Aplin, 1994).

Serum levels of CA15‐3 are considered normal if they are under the upper
limit of 25 U/ml (Bhatt et al., 2010). Elevated levels of CA15‐3 in women
with breast cancer were identified as being involved in the cancer’s
metastasis (Duffy, Shering, Sherry, McDermott, & O'Higgins, 2000). Of the
many different tumour markers that have been examined in breast cancer,
CA15‐3 is used most extensively as its expression in most breast cancers is
greatly increased (Clinton et al., 2003; O'Brien, Gough, Skehill, Grimes, &
Given, 1994). In women with breast cancer, where the disease status is
operable, around 11% of cases have elevated levels of CA15‐3, and in
those with metastatic breast cancer, 60% have elevated levels (Park, Oh,
Kim, & Kim, 2008). Post‐operative prognosis for patients with high CA15‐3
concentrations is much worse than for those with low concentrations,
although it has been found that patients with high serum CA15‐3 levels
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have a good response to more aggressive treatments (Park et al., 2008;
Shering, Sherry, McDermott, Higgins, & Duffy, 1998).

However, the sensitivity of CA15‐3 for marking breast cancer has been
reported as being low due to high levels in benign breast tissue diseases,
ovarian, lung, pancreatic, stomach, uterine and colorectal cancers and
hepatic dysfunction (Duffy et al., 2000; Nalini, Delphine, Silvia, Makhija, &
Uthappa, 2005; Sakaguchi, 2004). Elevated concentrations of CA15‐3 have
been found in patient serum where there is an absence of neoplasia (Trape
et al., 2011). In a study conducted on post‐menopausal women who were
all asymptomatic and healthy, 5.9% had serum concentrations of CA15‐3
higher than the cut‐off 25 U/ml (Dehaghani et al., 2007). CA15‐3 has been
found in the serum of patients with cobalamin deficiency and
macrocytosis in concentrations that are ten times the upper reference
limit for healthy people (Symeonidis et al., 2004). Amoura (2005) found
that 22% of patients suffering different inflammatory myopathies had
serum concentrations of CA15‐3 over the upper reference limit, suggesting
that there may be other factors influencing serum CA15‐3 concentrations.

Research into other tumour markers such as CA125, as mentioned
previously, has shown that the fluctuations in some tumour marker
concentrations are phase dependent in the menstrual cycle of healthy
women. Bon et al. (1999) described the differences in CA15‐3
concentrations in different phases of the spontaneous ovulatory cycle as
being not of statistical significance. However, another report found
conflicting results whereby they showed significant phase dependent
differences in CA15‐3 concentrations throughout the menstrual cycle
(Erbagci, Yilmaz, & Kutlar, 1999). Dehaghani et al. (2007) showed that a
group of women with a history of using the oral contraceptive pill for
greater than one year had a significantly larger number of subjects within
the normal range for CA15‐3, with only 1 out of the 76 women above the
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normal upper limit compared to 11 out of 127 women in the group of
women who did not use oral contraceptives.

Different studies have found that CA15‐3 concentrations in pregnancy
vary between slightly elevated, moderately elevated and significantly
elevated (Cheli et al., 1999; Panidis, Vlassis, Matalliotakis, Skiadopoulos, &
Kalogeropoulos, 1988). When comparing levels from each trimester,
although levels were shown to increase with gestation they do not cross
clinical thresholds (Bon et al., 2001; Correale et al., 1993; Schlageter et al.,
1998; Touitou et al., 1989). The rise in maternal serum concentrations of
CA15‐3 during the latter stages of pregnancy has been suggested to be due
to the proliferation of the breast epithelium during this phase or that it
might be an artefact of the immunoassay as it was developed against milk‐
fat globule membranes (Bon et al., 2001; Hilkens et al., 1984). Other
studies have found that concentrations of CA15‐3 do not change
significantly with pregnancy and that it can still be used as a biomarker for
breast cancer if gestational related reference ranges are put in place
(Botsis et al., 1999; Touitou et al., 1989).

1.4.1.4 Serum CA72‐4
CA72‐4 is a tumour associated antigen that is defined through its reactivity
with the two murine monoclonal antibodies CC‐49 and B72‐3 (Hareyama,
Sakuragi, Makinoda, & Fujimoto, 1996). CA72‐4 was once described as a
useful tumour marker for all epithelial derived tumours and gastric
carcinomas (Ohuchi, Takahashi, & Matoba, 1989). This research showed
that the sensitivity of CA72‐4 for gastric carcinoma was 38%, which is
greater than the tumour markers CA19‐9 which is 33%, CEA at 31% and
CA125 at 21% (Ohuchi et al., 1989; Villena, Lopez Encuentra, & Ecvhave
Sustaet, 1996). CA72‐4 was postulated as a complimentary biomarker to
CA125 in the screening of ovarian cancer, where one study found that
when combining the biomarkers the sensitivity for detecting early stage
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disease increased from 45% to 70% (Skates et al., 2004). With advances in
technology in recent years, immunoassays are now much more sensitive
so any evidence from this time is somewhat limited. These antibodies
recognise the tumour associated glycoprotein (TAG‐72) in the serum of
patients with various adenocarcinomas as well as in foetal epithelium
(Ohuchi et al., 1989; Villena et al., 1996).

1.4.2 Reproductive Markers
1.4.2.1 Reproductive Hormones
Reproductive hormones such as oestradiol, progesterone, luteinizing
hormone (LH) and human chorionic gonadotrophin (hCG) are measured
and evaluated as indicators of normal biological processes and events that
occur throughout the natural menstrual cycle and in pregnancy (O'Leary
et al., 1991; Sherman & Korenman, 1975). These hormones are also useful
tools in assisted reproductive medicine as they are measured throughout
exaggerated biological processes like those during hyperstimulated
ovarian cycles for IVF/ICSI to monitor follicle growth and endometrial
development (Wikland & Hillensjo, 2004).

During the menstrual cycle, oestradiol is produced in increasing amounts
by the granulosa cells of the developing follicle and when the follicle is
mature it will trigger luteinizing hormone to surge to induce ovulation.
The follicular phase is variable between women as shown by Cole, Ladner,
and Byrn (2009) where the timing of the LH peak was between 10‐20
days. The phase after ovulation is called the luteal phase which has been
shown to be consistent in length between women (McIntosh, Matthews,
Crocker, Broom, & Cox, 1980), where oestradiol and progesterone prepare
the endometrium for implantation and serum concentrations of
progesterone will start to increase from ovulation and are maintained by
the corpus luteum if pregnancy is achieved. Human chorionic
gonadotrophin (hCG) is a hormone produced by the chorion of the
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developing embryo from around 8 days post fertilisation where maternal
serum concentrations double every 2‐3 days. These reproductive markers
were measured in all women throughout this study to ensure accurate
timing of biological events throughout all three groups of cycles.

1.4.2.2 Pregnancy‐associated plasma protein‐A (PAPP‐A)
Pregnancy‐associated plasma protein‐A (PAPP‐A) was identified as one of
four proteins found in the serum of pregnant women in 1974 and was
later documented as being produced by the syncytiotrophoblastic cells of
the placenta where it is released in increasing amounts into maternal
circulation with increasing gestation (Folkersen, Grudzinskas, Hindersson,
Teisner, & Westergaard, 1981; Lin, Galbert, Kiefer, Spellacy, & Gall, 1974).
The concentration of maternally circulating PAPP‐A is reduced in the first
trimester of pregnancies that are affected by trisomy 18, trisomy 21,
blighted ova and is also associated with with IUGR (intra‐uterine growth
retardation) causing low birth weight, premature birth and pre‐eclampsia
(Brizot et al., 1996; D'Antonio et al., 2013; Dane, Dane, Batmaz, Ates, &
Dansuk, 2013; Poon, Maiz, Valencia, Plasencia, & Nicolaides, 2009; Smith
et al., 2002; NJ Wald, Watt, & Hackshaw, 1999; Yovich, Willcox,
Grudzinskas, Chapman, & Bolton, 1986). Early reports suggested that
reduced PAPP‐A concentrations in maternal serum are due to altered post‐
translational events which affect protein transport across the placenta or
its secretion, rendering PAPP‐A screening tests useful as a marker of
placental function (Brizot et al., 1996). First trimester combined screening
tests measure PAPP‐A and free β‐hCG at 9‐12 weeks as well as nuchal
translucency by ultrasound at 11‐13 weeks. This is combined with the
gestational age, maternal age and weight to give an estimate of the risk of
the foetus having trisomy 18 or 21 (bAmor et al., 2009).

Children born as a result of ART in 2008 accounted for 3.3% of all live
births in Australia (Y. A. Wang, Chambers, & Sullivan, 2010). There have
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been comparisons made between serum biomarker concentrations for
second trimester screening in naturally conceived pregnancies and IVF
conceived pregnancies. In some studies PAPP‐A levels were shown to be
reduced in pregnancies conceived via ART (Anckaert, Schiettecatte, Sleurs,
Devroey, & Smitz, 2008; bAmor et al., 2009; Bersinger et al., 2004; Hui et
al., 2005; Liao, Heath, Kametas, Spencer, & Nicolaides, 2001; Matilainen et
al., 2011; Maymon & Shulman, 2002a, 2004; Orlandi et al., 2002; Tul &
Novak‐Antolic, 2006), however in others there was no significant
difference (Bellver et al., 2005; Ghisoni et al., 2003; Lambert‐Messerlian et
al., 2006; Niemimaa et al., 2001; Wojdemann et al., 2001). Tul and Novak‐
Antolic (2006) found a correlation between the number of oocytes
retrieved with PAPP‐A concentrations, whereby higher oocyte numbers
results in a lower PAPP‐A, leading to the suggestion that the difference
may be due to the multiple corpora lutea present. bAmor et al. (2009)
found that PAPP‐A levels were reduced in both fresh and frozen‐thawed
embryo transfers when compared to naturally conceived pregnancies,
however, fresh transfers did have significantly lower PAPP‐A levels than
frozen‐thawed transfers. They also showed that there was no significant
difference in PAPP‐A levels between IVF, ICSI and GIFT subtypes of ART
pregnancies.

Increases in false‐positive rate (FPR) in prenatal screening tests for Down
syndrome have been reported for pregnancies conceived through assisted
reproduction (bAmor et al., 2009; Barkai et al., 1996; Frishman et al.,
1997; Lambert‐Messerlian et al., 2006; Orlandi et al., 2002; Ribbert et al.,
1996; N. Wald, White, Morris, Huttly, & Canick, 1999). Having a lower
PAPP‐A level at first trimester screening and therefore receiving a false‐
positive

result

(FPR)

might

subsequently

lead

to

unnecessary

amniocentesis procedures exposing these pregnancies to undue risk.
However, after adjustment for maternal age many other studies conclude
that the FPR is not increased in ART pregnancies (Bellver et al., 2005; Liao
et al., 2001; Matilainen et al., 2011; Maymon & Shulman, 2002b;
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Wojdemann et al., 2001). Contradictory results such as these suggest that
there may be many confounding factors on these prenatal screening tests
such as exogenous hormone treatment regimens which have been
suggested as the reason for lower PAPP‐A levels in these pregnancies
(bAmor et al., 2009; Bersinger et al., 2004; Hui et al., 2005; Tul & Novak‐
Antolic, 2006).

1.5 Aims of the Study
The study combined the measurement of several biomarkers using the latest
generation of immunoassays, with the serial monitoring of individual women in
three different reproductive situations namely natural and stimulated ovarian
cycles as well as early pregnancy. A better understanding of the behaviour of
such biomarkers in women may help us monitor reproductive events more
clearly, as well as assist in the clinical interpretation of these markers should
they be elevated above clinical threshold for disease. The aims of the present
study were therefore:
1. To use the current generation of immunoassays to measure selected
serum biomarkers (CA125, Prostate specific antigen [PSA], CA15‐3,
CA72‐4 and PAPP‐A) in women of reproductive age, and to describe the
assay performance characteristics at these levels.
2. Measure these compounds in disease‐free women during the natural
menstrual cycle, stimulated ovarian cycle and early pregnancy.
3. Identify changes in these biomarkers that may give additional
information about ovarian function, implantation and placentation.
4. Determine if these markers exceed the clinical thresholds associated
with disease, and identify any possible need to revise reference ranges
in the different reproductive phases.
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2 Materials and Methods
2.1 Participants
2.1.1 Ethics Approval
Ethics approval was granted by the Joondalup Health Campus Research
Ethics Committee [JHCREC, Project 1216] and the Edith Cowan University
Human Research Ethics Committee [ECUHREC, Project 7281], see appendices
1 and 2.

2.1.2 Selection of Participants
Participants recruited for this research project were women attending
Fertility North for fertility treatment. None of the women had evidence of
cancer or endometriosis. On each given day that the clinic was open, women
on current treatment plans came to the clinic in the morning between
7:00am and 8:30am to have their blood taken as part of their management.
To identify which patients were due for blood collection on each day, we used
an electronic diary (Genie; Genie Solution Pty Ltd, Indooroopilly,
Queensland) which lists all women attending the clinic on that day. The
program permits all of the patient’s medical information and history to be
retrieved at any given time. On each day during the recruitment period, the
list of patients was screened to determine which women were attending for
their first blood sample of their cycle that day and what type of treatment
they were starting. If they were day 2 of a natural cycle or a fresh IVF or ICSI
cycle, these women were approached that morning and recruited using the
information letter and consent forms approved by the two governing ethics
committees. If there were any women starting a pregnancy monitoring cycle
of blood sampling then these women were also approached in the same
manner.
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2.1.3 Study Cycles
2.1.3.1 Natural Menstrual Cycle
Participants in this study group included women who were attending
Fertility North for a tracking cycle which takes place in the initial
investigation prior to commencing fertility treatment. These women are
on no medications that affect the natural reproductive cycle e.g. the oral
contraceptive pill or hormone replacement therapy. Blood was taken on
day 2‐3 of the natural cycle, where the first day of menses is called day 1.
Oestradiol, progesterone, LH and FSH are measured from this first sample.
The next blood sample was taken 5‐7 days later when the oestradiol,
progesterone and luteinizing hormone concentrations were measured.
These three hormones were measured until ovulation. Ovulation was
defined as being when there was a serum LH surge and a rise in
progesterone concentration from a baseline level. This was then
confirmed by ovarian ultrasound when the leading follicle could be seen.
Seven days after ovulation the woman’s oestradiol and progesterone
concentration were measured as an indication of luteal function, and then
at fourteen days after ovulation a pregnancy test was performed by
measuring oestradiol and progesterone as well as human chorionic
gonadotrophin (hCG).

2.1.3.2 Stimulated Ovarian Cycle
Participants in this study group included women starting an IVF or ICSI
cycle at Fertility North. These women had their blood taken on day 2 of
their cycle where the oestradiol, progesterone, luteinizing hormone and
follicle stimulating hormone concentrations were measured. The women
embarked on a stimulatory regimen using a protocol including either a
GnRH agonist in a short down regulation (flare) cycle (Frydman et al,
1988; Garcia et al, 1990; Acharya et al, 1992), long down regulation cycle
(Porter et al, 1984; Shaw et al, 1985) or a GnRH antagonist in an
antagonist cycle (Diedrich et al, 1994). After 6 days of receiving FSH
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injections the women returned for another blood test to measure their
oestradiol and follicle stimulating hormone levels to gauge their response
to stimulation. The oestradiol levels were measured approximately every
2 days during stimulation to further monitor the ovarian response and
identify whether an increased dose of FSH was required due to a low
response, or if the woman was at risk of ovarian hyperstimulation
syndrome (OHSS) because of an inordinately high response. Seven days
after the patient was triggered to ovulate, another blood test was
performed to measure the oestradiol and progesterone levels. At fourteen
days after ovulation, the patient had a pregnancy test indicating oestradiol,
progesterone and human chorionic gonadotrophin (hCG) concentrations.
If the woman was pregnant she had a blood test every two or three days to
measure her progesterone and hCG levels until she had a visible foetal
heart beat identified by ultrasound around seven weeks gestation.

2.1.3.3 Early Pregnancy
Participants in this group included women who had undergone fertility
treatment at Fertility North and had become pregnant as a result of this
treatment. At fourteen days after ovulation women had a pregnancy test
which measured their oestradiol, progesterone and human chorionic
gonadotrophin (hCG) levels. A hCG concentration of >25 IU/mL is
regarded as a positive pregnancy test and the hCG concentration should
approximately double every two to three days. Therefore, blood samples
were taken every two to three days during an early pregnancy monitoring
cycle, until the woman had an ultrasound scan at around 6‐7 weeks of
gestation. Women in this study group take one 200mg Progesterone BD
pessary (Orion, Balcatta WA) which helps to support the pregnancy.

2.2 Serum Collection & Storage
All blood samples were collected by Fertility North phlebotomists on site. Blood
was collected using syringes and transferred into 5ml Vacutainer SST™ tubes
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(Becton Dickinson, UK), labelled and bagged, before delivery to the laboratory
with a request form. Receipt of the sample by the laboratory was then
confirmed by adding the patient and requested tests to the “blood” screen in
Genie for that day, and selecting the patient as per the daily blood samples. The
sample was then allocated a laboratory number, with copies of the bar code
being placed on the blood tube and on the pathology referral form. The blood
was allowed to clot at room temperature and then centrifuged at 4000rpm for 4
minutes. The sample was then analysed for the requested reproductive
hormones according to the patient’s treatment and then stored at ‐80˚C for
retrospective analysis of tumour markers at a later date. Once each patient had
finished having blood samples collected, all of the blood samples from that
completed treatment cycle were thawed at room temperature and then
analysed for biomarker concentrations in one batch analysis on the same day
that they were thawed. Once the sample was analysed, any excess serum was
replaced into the ‐80˚C freezer for storage. The research detailed in this thesis
was carried out between February 2012 and December 2013.

2.3 Determination of Serum Hormone Concentration
The Siemens Centaur CP Automated Analyser (Siemens, Bayswater, Victoria
3053, Australia) was used to measure oestradiol, luteinising hormone (LH),
progesterone and human chorionic gonadotrophin (hCG).

2.3.1 Basic Assay Procedure
The automated analyser was run daily according to the manufacturer’s
instructions and the standard operating procedure of Fertility North
[Appendix 3]. All reagents were stored and used as per the manufacturer’s
instructions as shown in Table 1 and Appendix 5 [Chapter 3]. To reconstitute
calibrators and control material, the pipette pump with a glass volumetric
pipette was used to deliver deionised water (Ibis Technology, Mt Hawthorn).
A record of the sample, the date of reconstitution and the date of expiry were
written on the side of the reagent bottles.
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2.3.2 Internal and External Quality Control
Internal quality control for each assay was performed using the BioRad
Immunoassay Plus 1, 2, 3 (Bio‐Rad Laboratories, Irvine, CA) in each run.
Ligands were reconstituted to 5 mls and 7 x 600µl lots aliquotted for the next
7 days. All results were stored by the Advia Centaur CP automatically and
transferred to a computer on a monthly basis into QC reporter 2. A repeat
patient sample from the previous day was also run and results recorded
daily. All of the reproductive hormone assays were also assessed using two
external quality assurance schemes named RCPA Endocrine scheme (RCPA,
New South Wales) and EQASRM (EQASRM, Western Australia). These
schemes were used as a means to compare the results generated from the
method being used to the results of other laboratories in the country that are
also using the same method.

2.4 Determination of Serum Biomarker Concentration
The Roche Cobas e411 Automated Analyser (Roche Diagnostics, Germany) was
used to measure the biomarkers; PAPP‐A, CA125, CA15‐3, CA72‐4 and total PSA
(tPSA). This was done as a batch analysis to minimise variability attributable to
the reagent stability.

2.4.1 Basic Assay Procedure
The automated analyser was run daily according to the manufacturer’s
instructions, and the standard operating procedure of Fertility North
[Appendix 4]. All reagents were stored and used as per the manufacturer’s
instructions as shown in Table 2 and Appendix 6 [Chapter 3]. The lyophilized
calibrators and control material were reconstituted with deionised water
(Ibis Technology, Mt Hawthorn) as shown in Appendix 7. A record of the
sample the date of reconstitution and the date of expiry was written on the
side of the reagent bottles. The reagent kits were stored in the biochemistry
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refrigerator at 2‐8˚C until use. After opening, they were stable for 12 weeks at
2‐8˚C or 3‐8 weeks on‐board the analyser. When in use reagent packs were
removed from the fridge and placed on the reagent rotor with the lids
unclipped after coming to room temperature. The temperature of the rotor
was controlled at 20˚C. Reagents were left to warm to this temperature
before use. The rotor lid was replaced and locked once all reagent packs were
loaded. After use, the lids on the reagent bottles were snapped closed and the
reagent is placed back into the refrigerator for storage until its next use.

2.4.2 Calibrations
The reagent kits were calibrated within 24hours after the initial opening.
Thereafter, renewed calibrations were required every 7 days per reagent kit
until all tests were used. The Roche CalSet specific to each of the assays were
used to calibrate the reagent kits. The calibrators come in liquid and
lyophilized form and were all stored at 2‐8˚C on receipt and these were stable
until the stated expiry date. The lyophilized calibrators were reconstituted as
per the manufacturer’s instructions and once reconstituted the calibrators
were stored at 2‐8˚C where they were stable for 6 weeks. Aliquots of
reconstituted calibrator were frozen at ‐20˚C where they were stable for 12
weeks until thawed for use. The calibrators were left to warm to room
temperature before use and the reconstituted aliquots were used only once.

2.4.3 Internal and External Quality Control
Internal quality control was assessed using the Elecsys PreciControl Tumor
Marker (Roche Diagnostics, Germany) with two levels, the BioRad Lyphochek
Tumor Marker Plus Control (Bio‐Rad Laboratories, Irvine, CA) and the
Elecsys PreciControl Maternal Care (Roche Diagnostics, Germany) with three
levels, which were run each day that an assay was performed and after every
calibration. The CA125 assay was enrolled in an external quality assurance
scheme (RCPA, Endocrine scheme) under Fertility North however there were
no external quality assurance schemes available for the other biomarker
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assays. Reconstitution details and stability of the quality control material are
given in Appendix 7. The assay’s performance characteristics are described in
Table 1 [Chapter 3].

2.5 Statistical Analysis
Measurement of quality control samples was expressed as the mean and
standard deviation, to allow the calculation of coefficients of variation. However,
the results of clinical samples are expressed as means and standard error of the
mean (sem) as an estimate of how close to the population mean the sample
mean is likely to be.

For the ovarian cycle analyses, a linear mixed effects model was used to test the
mean differences in marker concentration between women in stimulated and
natural cycles across the cycle phases. For each model, the response variable
(CA125, tPSA, CA153 and PAPP‐A) was log transformed before analysis as the
data appeared non‐normal and thus the error distribution might affect the
calculation of standard errors and the p‐values required for null hypothesis
testing. Group (IVF and ‘natural’) and Phase were included as fixed effect factors
and ‘Subject’ and ‘Time’ were modelled as random effects (as in some subjects
there were multiple time points measured within phases). The interaction
between Group and Phase was also modelled. The analysis was done using the R
version 3.0.0 computing software (R Core Team, 2013). Models were built using
the ‘nlme’ (Pinheiro, Bates, DebRoy, Sarkar, & R Development Core Team, 2012).
Small sample size and gaps in IVF sampling due to the nature of IVF need to be
taken into account in cautiously interpreting this data.

For the early pregnancy analyses the response variable (tPSA, CA125, CA15‐3,
PAPP‐A and hCG) was log transformed before analysis as the data appeared
non‐normal and thus the error distribution might affect the calculation of
standard errors and the p‐values required for null hypothesis testing. Gestation
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was included as fixed effect factors and ‘Subject’ and ‘Time’ were modelled as
random effects (as in some subjects there were multiple time points measured
within the phase). The interaction between Group and Gestation was also
modelled. The analysis was done using the R version 3.0.0 computing software
(R Core Team, 2013). Models were built using the ‘nlme’ (Pinheiro et al., 2012)
mixed models package and graphics were produced using the ‘ggplot2’ package
(Wickham, 2009).

2.6 Day and Phase of Cycle
The menstrual cycle, as described earlier, is considerably variable in length from
day one of the cycle to ovulation. In order to normalise the follicular phase for
statistical analysis a formula was applied to calculate an adjusted day (Hadlow
et al., 2013).
Adjusted day = Actual day x (14/Actual day of ovulation)
The menstrual cycle was further divided into seven phases using the day of the
cycle (Hehenkamp et al., 2006) relative to ovulation as;
(1) Early Follicular (EF) ‐ 10 days or more before ovulation
(2) Mid Follicular (MF) ‐ 6 to 9 days before ovulation
(3) Late Follicular (LF) ‐ 2 to 5 days before ovulation
(4) Periovulatory (PO) ‐ 1 day before ovulation
(5) Ovulation (O) ‐ the day of ovulation
(6) Mid‐Luteal (ML) – 5 to 8 days after ovulation
(7) Late Luteal (LL) – 9 to 14 days after ovulation
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3.0 Results
3.1 Performance characteristics of Roche automated immunoassays
used to measure CA125, tPSA, CA15‐3, CA72‐4 and PAPP‐A.
Results obtained with the Biorad Lyphochek Tumor Marker Plus trilevel quality
control, Roche Elecsys PreciControl Tumor Marker QC bi‐level quality control
material and Roche Elecsys PreciControl Maternal Care QC tri‐level quality
control material are shown in Table’s 1 and 2 . The reproducibility of results
from each assay was described by calculating the coefficient of variation (CV).
Good reproducibility was shown in the measurement of CA125 (CV <6.2%) and
CA15‐3 (CV <7.5%). PAPP‐A and tPSA were more variable (CV <11.4% and
<13.4% respectively) and CA72‐4 was more so (CV <20.4%). The BioRad QC
material appeared to give greater reproducibility compared to the Roche QC
such that all of the CV’s were lower for the BioRad QC for 6 of the 8 QCs.

The variability associated with the measurement of serum is shown in Table 3
where pooled serum from women recruited in the study was analysed daily.
Similar patterns were seen with the CA125 (CV <4.7%) and CA15‐3 (CV <6.5%).
However, the low concentrations of CA72‐4, PAPP‐A and tPSA resulted in higher
variability with CVs of <24.1%, <27.0% and <38.5% respectively. Estimates of
within‐run variability seen with clinical samples are shown in Table 4, with
PAPP‐A, CA125, CA15‐3 and CA72‐4 all being <5.0%. tPSA was more variable
with a CV of 12.94%.
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Table 1. Between‐run variability assessed using commercially
available quality control material (CA125, CA15‐3, CA72‐4 and
tPSA).

Marker

Biorad Lyphochek Tumor

Elecsys PreciControl

Marker Plus

Tumor Marker

Level

µ ± sd

CV (%)

µ ± sd

CV (%)

CA125

Low

28.45 ± 1.46

5.12

28.52 ± 1.75

6.13

U/ml

Medium

70.67 ± 4.02

5.69

‐

‐

(n=43)

High

194.66 ± 6.74

3.46

87.30 ± 4.40

5.04

CA15‐3

Low

22.25 ± 1.41

6.32

18.52 ± 1.39

7.49

U/ml

Medium

57.12 ± 3.97

6.95

‐

‐

(n=42)

High

111.48 ± 7.55

6.77

84.58 ± 5.85

6.92

CA72‐4

Low

4.54 ± 0.87

19.15

4.94 ± 1.01

20.44

U/ml

Medium

11.98 ± 1.72

14.33

‐

‐

(n=33)

High

44.84 ± 3.25

7.26

44.75 ± 5.19

11.61

tPSA

Low

0.072 ± 0.01

13.39

‐

‐

ng/ml

Medium

3.30 ± 0.29

8.84

3.90 ± 0.35

9.04

(n=45)

High

15.55 ± 1.45

9.31

39.33 ± 3.63

9.23

Table 2. Between‐run variability assessed using commercially
available quality control material (PAPP‐A).
Marker

Level

PAPP‐A

Elecsys PreciControl Maternal Care
µ ± sd

CV (%)

Level 1

5535.63 ± 629.03

11.36

mIU/L

Level 2

2761.58 ± 256.88

9.30

(n=38)

Level 3

271.42 ± 20.65

7.61
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Table 3. Pooled human serum showing between‐run variability.
Pool A

Pool B

Pool C

Marker
µ ± sd
CA125 U/ml

27.18±

(n=23)

0.98

CA15‐3 U/ml

15.51±

(n=21)

0.94

CA72‐4 U/ml
(n=15)

2.37± 0.46

tPSA ng/ml

0.007±

(n=22)

0.001

PAPP‐A mIU/L

9.04±

(n =22)

1.31

CV (%)
3.59
6.09
19.45
16.88

µ ± sd

CV (%)

36.58±

4.18

1.53
15.68±

6.49

1.02
1.28± 0.31

24.05

0.003±

38.46

0.001
6.19±

14.47

26.99

1.67

µ ± sd

CV (%)

40.36±

4.67

1.88
16.45±

6.00

0.99
1.66± 0.38
0.004±
0.001

22.86
28.87

37.15±

4.54

1.69

Table 4. Pooled human serum showing within‐run variability.
Pooled Serum

Marker

µ ± sd

CV (%)

CA125 U/ml (n=25)

36.20 ± 0.90

2.48

CA15‐3 U/ml (n=25)

15.70 ± 0.33

2.07

CA72‐4 U/ml (n=25)

1.28 ± 0.06

4.68

tPSA ng/ml (n=25)

0.006 ± 0.001

12.94

PAPP‐A mIU/L (n = 25)

9.25 ± 0.21

2.25
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3.2 Natural and Stimulated Ovarian Cycles
3.2.1 Length of Follicular Phase
The day of ovulation (as defined in 2.1.3.1) for the 10 natural cycles is shown
in Figure 1 (a). It was extremely variable, ranging from day 10 to day 25. The
day of ovulation in the 11 cycles stimulated with exogenous gonadotrophin is
shown in Figure 1 (b). This was less variable than the natural cycles, ranging
between day 12 and day 15 of the cycle.

3.2.2 Reproductive Hormones
The reproductive hormone concentrations in natural and stimulated ovarian
cycles are shown in Table 5. In the early follicular phase the oestradiol
concentrations are similar between natural (165.6±11.8pmol/L) and
stimulated cycles (156.0±6.6pmol/L). Large differences in oestradiol are seen
by the mid‐follicular phase where natural cycle concentrations increase by a
factor of ~1.6 times to an average of 265.0±43.0pmol/L compared to an
increase by a factor of ~7.3 times to an average of 1133.7±241.1pmol/L in
stimulated cycles. The oestradiol concentrations in the late follicular phase in
natural cycles on average doubled to 528.0±51.2pmol/L compared to an
increase by a factor of ~3.5 to an average of 3980.0±435.8pmol/L in the
stimulated cycles. Seven days after ovulation the oestradiol concentrations in
both cycles decreased slightly to 484.8±68.4pmol/L in natural cycles and
2187.0±301.1pmol/L in stimulated cycles.

Progesterone remained relatively constant throughout the early follicular,
mid‐follicular

and

late

follicular

phases

in

natural

cycles

where

concentrations ranged from 1.3±0.2‐1.9±0.3nmol/L. It wasn’t until after
ovulation during the mid‐luteal phase that progesterone was seen to increase
in natural cycles (36.5±4.6nmol/L). Progesterone was only measured in the
early follicular and mid‐luteal phase during stimulated cycles. The
progesterone concentration in stimulated cycles (2.3±0.6nmol/L) was similar
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to natural cycles (1.9±0.3 nmol/L) in the early follicular phase however
concentrations were much greater in the mid‐luteal phase of stimulated
cycles (197.2±30.0) compared to the mid‐luteal concentrations in natural
cycles (36.5±4.6).

Table 5. Reproductive hormone concentrations (mean±sem) in
natural and stimulated ovarian cycles. The stage of the cycle was
classified as early follicular (EF), mid‐follicular (MF), late
follicular (LF) and mid‐luteal (ML).
Oestradiol (pmol/L)

Progesterone (nmol/L)

Stage
Natural

Stimulated

Natural

Stimulated

EF

165.6±11.8

156±6.6

1.9±0.3

2.3±0.6

MF

265.0±43.0

1133.7±241.1

1.4±0.2

‐

LF

528.0±51.2

3980.0±435.8

1.3±0.2

‐

ML

484.8±68.4

2187.0±301.1

36.5±4.6

197.2±30.0
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Figure 1. Day of ovulation for women during (a) Natural cycles,
and (b) Stimulated cycles.
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3.2.3 Changes in serum CA125, CA15‐3, CA72‐4, tPSA and PAPP‐A
concentrations.
Serum concentrations of CA125, CA15‐3, CA72‐4, tPSA and PAPP‐A during
natural and stimulated cycles are shown in Tables 6 and 7. When comparing
results from natural versus stimulated ovarian cycles, CA125 concentrations
showed no significant difference (p=0.5989) [Table 8]. Concentrations of
CA125 were however significantly influenced by the stage of the ovarian
cycle (p=<0.0001). In natural menstrual cycles, the concentration of CA125
was highest during the early follicular phase of the cycle, which is concurrent
with menstruation (25.92±4.45 U/ml) and lowest in the late‐follicular phase
prior to ovulation (16.76±2.39 U/ml) [Table 6 & Appendix 8]. In stimulated
ovarian cycles, concentrations of CA125 were highest during the late luteal
phase just prior to menstruation (23.57±3.91 U/ml) and lowest at the mid‐
follicular phase (13.41±1.90 U/ml) [Table 7 & Appendix 8].

All samples in the ovarian cycles had detectable levels of CA15‐3 [Tables 6
and 7]. One individuals sample from the natural cycle group (29.54 U/ml)
and one from the stimulated group (29.51 U/ml) measured above the clinical
cut‐off value for CA15‐3 of 25 U/mL, however all other samples from both
individuals were below the clinical cut‐off. There was no significant
difference in the CA15‐3 concentration between natural and stimulated
ovarian cycles (p=0.8694) as shown in Table 9.

However, there were

significant differences in concentrations seen between the phases of the cycle
(<0.0001) [Table 9]. In natural menstrual cycles the concentration of CA15‐3
was highest in the mid‐follicular phase (17.52±2.31 U/ml) and lowest in peri‐
ovulation (13.67±1.51 U/ml) [Table 6].

Total prostate specific antigen (tPSA) was detectable in 6/10 (60%) of
women at some point in the natural menstrual cycle and 10/11 (91%) of
women in stimulated cycles. Concentrations of tPSA were low during natural
and stimulated cycles and there was no significant difference in tPSA
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concentrations between natural cycles and stimulated cycles (p=0.9193), or
between different stages of the cycle (p=0.8769) [Table 10]. The
concentration of tPSA was highest in the early follicular and late luteal phase
which coincides with menstruation, however this did not reach statistical
significance [Table 6].

There were 6/10 (60%) of the individuals in natural menstrual cycles and
6/11 (54.5%) of individuals in the stimulated cycles that had detectable
levels of CA72‐4 for at least one of the samples. CA72‐4 concentrations were
overall on average 1.47±0.31 U/ml in natural cycles and 1.58±0.35 U/ml in
stimulated ovarian cycles. There was a larger degree of variation between the
individuals than there was at different phases of the cycles [Table 6]. The
results are very unstable and inconsistencies are greatest for CA72‐4
compared to the other biomarkers.

All samples had detectable levels of PAPP‐A in natural and stimulated cycles.
There was no evidence of any significant changes in the mean concentration
of PAPP‐A during natural and stimulated ovarian cycles (p=0.4859) and there
was no evidence for an interaction effect between PAPP‐A concentrations
and the phase of the cycle (p=0.8491)[Table 11]. There was however a
significant difference in PAPP‐A concentrations in the natural cycles
compared to the stimulated cycles whereby on average the mean PAPP‐A of
the natural group was 2.41±0.58 mIU/L higher than the stimulated group (p<
0.0001)[Table 11].
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Table 6. Biomarker concentrations (mean ± sem) during the
natural menstrual cycle.
CA125

CA15‐3

CA72‐4

tPSA

PAPP‐A

(U/ml)

(U/ml)

(U/ml)

(ng/ml)

(mIU/L)

25.92±4.45

15.59±1.67

1.86±0.92

0.012±0.009

8.97±0.79

21.36±3.21

17.52±2.31

1.21±0.50

0.007±0.004

8.91±1.04

16.76±2.38

15.91±1.69

1.10±0.33

0.009±0.006

8.59±0.64

17.91±2.64

13.67±1.51

2.46±1.47

0.009±0.006

9.28±0.90

Ovulation

17.49±2.80

15.26±1.91

1.65±0.80

0.008±0.004

8.8±0.99

Mid‐Luteal

20.39±1.83

16.85±1.94

1.04±0.31

0.004±0.002

8.40±0.81

Late Luteal

19.77±2.51

15.03±1.95

1.52±0.96

0.012±0.006

8.30±0.89

Phase
Early
Follicular
Mid‐
Follicular
Late‐
Follicular
Peri‐
Ovulatory
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Table 7. Biomarker concentrations (mean ± sem) during
stimulated ovarian cycles.
CA125

CA15‐3

CA72‐4

tPSA

PAPP‐A

(U/ml)

(U/ml)

(U/ml)

(ng/ml)

(mIU/L)

17.06±2.37

15.10±2.00

2.33±1.12

0.0036±0.004

6.24±0.54

13.41±1.90

14.18±2.09

1.13±0.39

0.0085±0.002

6.73±0.59

13.62±1.64

14.60±1.90

0.98±0.27

0.0036±0.003

6.57±0.35

Mid‐Luteal

22.89±13.45

16.99±2.15

1.72±0.88

0.0151±0.001

6.19±0.53

Late Luteal

23.57±3.91

16.84±2.23

1.53±1.01

0.0053±0.004

5.97±0.49

Phase
Early
Follicular
Mid‐
Follicular
Late‐
Follicular

Table 8. ANOVA table for the analysis of the concentration of
CA125 in natural and stimulated cycles across phases.
CA125

numDF

denDF

F‐value

p‐value

(intercept)

1

90

926.1185

<0.0001

Group

1

19

0.2862

0.5989

Phase

1

90

6.2613

0.0141

Group:phase

1

90

21.5411

<0.0001
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Table 9. ANOVA table for the analysis of the concentration of
CA15‐3 in natural and stimulated ovarian cycles across phases.
CA15‐3

numDF

denDF

F‐value

p‐value

(intercept)

1

91

756.9088

<0.0001

Group

1

19

0.0278

0.8694

Phase

1

91

35.4565

<0.0001

Group:phase

1

91

23.0392

<0.001

Table 10. ANOVA table for the analysis of the concentration of
Prostate Specific Antigen (tPSA) in natural and stimulated ovarian
cycles across phases.
PSA

numDF

denDF

F‐value

p‐value

(intercept)

1

67

734.6268

<0.0001

Group

1

14

0.0107

0.9193

Phase

1

67

0.0157

0.9006

Group:phase

1

67

0.0242

0.8769

Table 11. ANOVA table for the analysis of the concentration of
Pregnancy Association Plasma Protein‐A (PAPP‐A) in natural and
stimulated ovarian cycles across phases.
numDF

denDF

F‐value

p‐value

(Intercept)

1

96

768.6488

<.0001

Group

1

25

56.8412

<.0001

Phase

1

96

0.4893

0.4859

Group:Phase

1

25

0.8491

0.8491
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3.3 Early Pregnancy
3.3.1 Reproductive hormones
The serum hCG concentrations increased from 296.8±70.9 at 4 weeks to
52191.3±11310.7 at 7 weeks [Table 12]. This increase in hCG during early
pregnancy is highly significant (p=<0.0001) [Table 13]. Progesterone
concentrations were steady ranging from 179.2±42.1 at week 4 to
287.8±78.8 at week 7 of gestation [Table 12].

3.3.2 Serum PAPP‐A, CA125, CA15‐3, CA72‐4 and tPSA.
The PAPP‐A, CA125, CA15‐3, CA72‐4 and tPSA biomarker concentrations are
shown in Table 17. The concentration of PAPP‐A increased steadily from
6.51±0.56mIU/L at 4 weeks to 125.38±54.2mIU/L at 7 weeks. The changes
seen in early pregnancy were highly significant (p=<0.0001) for PAPP‐A
[Table 14] and all pregnancies were viable and resulted in a live birth.

The concentrations of CA125 in early pregnancy are shown in Table 18.
There was a significant effect of the stage of gestation on CA125
concentration (p=0.0012) [Table 15 & Appendix 9]. However, there was
considerable variability in the timing of peak CA125 [Figure 2]. When the
values are normalised to the time of peak value there are clear patterns of
change in CA125 concentration [Figure 3].
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Figure 2. A frequency distribution of the time of peak CA125
concentration for 14 pregnant women.

Figure 3. The serum CA125 concentration (U/ml) relative to the
time of the peak concentration for 14 pregnant women.
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There were 9/14 (64%) of the pregnant women that had detectable levels of
tPSA in at least one sample during early pregnancy. The concentration of PSA
increased steadily from 0.005±0.001 at 4 weeks to 0.01 ± 0.003 at 7 weeks
[Table 18 & Appendix 9], with an average increase of 0.0015 ± 0.0004ng/ml
for every one unit increase in gestation time (p=0.000 ) [Table 16]. In effect,
the concentration of tPSA in maternal serum on average doubled from week
four to seven of gestation.

All participants had detectable levels of CA15‐3 throughout early pregnancy
where there was a significant effect of the stage of gestation on the CA15‐3
concentration (p=0.000) [Table 17 & Appendix 9]. The average concentration
of CA15‐3 was 16.44±2.22U/ml at 4 weeks gestation and over the time
period reduced to an average of 12.97±2.35U/ml [Table 17]. These
concentrations were all below the clinical cut‐off value of 25U/ml.

Of the participants, only 57% of women in early pregnancy had detectable
levels of CA72‐4 for at least one of their samples. The clinical cut‐off values
for CA72‐4 are variable and transferability of expected values to individual
laboratories can be considerably different. The CA72‐4 concentration in
pregnancy was on average 2.14±3.5U/ml, however, because of the variability
of results both within‐individuals and between‐individuals a statistical
analysis was not performed as the distribution did not fit the linear mixed
effects model.
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Table 12. Reproductive hormone concentrations (mean±sem) in
early pregnancy according to the gestational age.
Hormone Concentrations
Gestation

Oestradiol

Progesterone

(pmol/L)

(nmol/L)

4 weeks

1797.5±394.3

179.2±42.1

296.8±70.9

4.5 weeks

‐

179.7±43.5

1773.0±262.0

5 weeks

‐

179.3±37.2

5359.6±1212.8

5.5 weeks

‐

196.8±43.4

15085.9±2666.5

6 weeks

‐

169.3±34.9

31725.0±5367.8

6.5 weeks

‐

167.9±42.5

48306.0±7371.0

7 weeks

‐

287.8±78.8

52191.3±11310.7

hCG (IU/L)

Table 13. ANOVA table for the linear mixed effects model for hCG
levels during pregnancy.
hCG

numDF

denDF

F‐value

p‐value

(Intercept)

1

69

5634.490

<0.0001

Gestation

1

69

1153.922

<0.0001

Table 14. ANOVA table for the linear mixed effects model for
PAPP‐A levels during pregnancy.
PAPP‐A

numDF

denDF

F‐value

p‐value

(Intercept)

1

69

1094.4500

<0.0001

Gestation

1

69

549.0459

<0.0001
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Table 15. ANOVA table for the linear mixed effects model for
CA125 levels during pregnancy.
CA125

numDF

denDF

F‐value

p‐value

(Intercept)

1

69

207.11741

<0.0001

Gestation

1

69

11.38667

0.0012

Table 16. ANOVA table for the linear mixed effects model for
Prostate Specific Antigen (tPSA) levels during pregnancy.
PSA

numDF

denDF

F‐value

p‐value

(Intercept)

1

45

2967.6833

<0.0001

Gestation

1

45

15.6762

0.000

Table 17. ANOVA table for the linear mixed effects model for
CA15‐3 levels during pregnancy.
CA15‐3

numDF

denDF

F‐value

p‐value

(Intercept)

1

69

528.8371

<0.0001

Gestation

1

69

15.7576

0.000
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Table.18 Biomarker concentrations (mean ± sem) during early pregnancy.
Gestation

CA125

CA15‐3

CA72‐4

tPSA

PAPP‐A

(Weeks)

(U/ml)

(U/ml)

(U/ml)

(ng/ml)

(mIU/ml)

4

22.79

16.44

2.15

0.005

6.51

(n=7‐9)

±3.73

±2.22

±1.08

±0.001

±0.56

4.5

30.40

15.19

2.19

0.005

6.86

(n=9‐14)

±6.02

±1.56

±1.05

±0.001

±0.40

5

47.65

14.59

2.42

0.006

8.29

(n=9‐14)

±15.12

±1.60

±1.24

±0.001

±0.66

5.5

57.98

14.30

2.15

0.007

14.58

(n=9‐14)

±27.45

±1.58

±1.08

±0.001

±1.47

6

48.15

14.28

1.68

0.008

34.41

(n=9‐14)

±19.13

±1.54

±0.66

±0.001

±4.45

6.5

42.59

14.04

1.79

0.009

59.37

(n=8‐13)

±10.56

±1.53

±0.74

±0.001

±7.09

7

29.92

12.97

2.60

0.010

125.38

(n=4‐6)

±6.44

±2.35

±1.40

±0.003

±22.11

4.0 Discussion
4.1 Assay Characteristics
The use of immunoassays allows precise quantitative measurements to be made
when measuring analytes. However, different assays often have different
characteristics due to the choice of reagent or their calibration, resulting in
different numerical values. This is important when comparing work from
various laboratories or over a range of time frames. For example, the expression
of PAPP‐A results in mIU/ml in the present study compared to µg/L elsewhere
(Sinosich, Porter, Sloss, Bonifacio, & Saunders, 1984; Yovich et al., 1986) reflects
the change in methodology and the move to a different standardisation.
Between‐assay differences have been reported when measuring CA15‐3 with
commercial kits from different companies, resulting from differences in the
antibodies produced against different sections of the antigen as well as
calibration rather than specificity (Klee & Schreiber, 2004). This is perhaps not
too surprising as many of the companies used similar capture and signal
antibodies in their sandwich immunometric assays. Different CA125 assays
have used different reference preparations, such that results are then expressed
in different units. Whilst the current study used an assay with results in U/ml,
Tavmergen et al. (2001) used a method reporting in IU/ml. The performance of
the CA125 assays can also show between‐supplier variability, and large
differences have been reported between assays supplied by Siemens and
Panomics (McLemore et al., 2012).

Secondary to the variation seen between the assays used in different research
projects, there is also some variation associated with using the same assay in
different runs. The between‐batch assay variation differs amongst analytes and
so it is important to assess the between‐batch variation associated with the
method being used to ensure that any changes seen are the result of biological
fluctuations and not because of the assay variation. In this present study the
between‐batch variation was further compared with the within‐batch variation
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to ensure that the method used only had the smallest assay variation associated
with the results. The assessment of the between‐batch variation was done by
measuring artificial quality control (QC) material from both the company that
manufactures the assay and an external source on up to 45 different occasions.
Along with the manufactured QC samples, pooled human serum was also
analysed to assess the assays at levels found in our study population.

The results for the between‐batch variation measured using the commercial QC
material showed good reproducibility for the CA125 and CA15‐3 assays
however the PAPP‐A, tPSA and CA72‐4 assays showed considerably greater
variability. The results obtained using the pooled human serum showed similar
patterns for CA125 and CA15‐3 however again the lower concentrations of the
tPSA, CA72‐4 and PAPP‐A in the pooled human serum resulted in a larger
degree of variability. The results for the within‐batch variation measured using
the pooled human serum show good reproducibility whereby the within‐batch
variation for CA125, CA15‐3, CA72‐4 and PAPP‐A all show CVs of <5.0%. The
within‐batch results for tPSA were more variable than the other assays however
the serum concentrations for tPSA are lower in females and thus near the assays
lower limit of detection. The difference in the between‐batch variation and
within‐batch variation shows that the analysis of longitudinal samples from
individual women should be done in one batch analysis where possible. This
ensures that any changes seen in the concentrations of the biomarkers are due
to biological fluctuations and it reduces the interference that might be the result
of the assay itself.

4.2 Ovarian Cycles
The lengths of the follicular phase in the natural cycles included in this present
study were variable ranging between 10‐25 days. This is similar to previous
work performed by Cole et al. (2009) which showed the distribution of the LH
peak as being between 10‐20 days, and Lenton, Landgren, and Sexton (1984)
who reported a distribution of 8.2‐21 days. The range of lengths of the follicular
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phase in stimulated cycles was less, being between 12‐15 days as they were all
controlled ovarian cycles and the differences in days is attributable to the
individual response to the stimulation protocol. The hormone levels in all cycles
followed the classical patterns of change, confirming that the modelling and
expression of results according to the stage of cycle is appropriate.

There were phase dependent changes seen in CA125 concentrations for both
natural and stimulated ovarian cycles. This study showed that there was no
effect of ovarian hyperstimulation on CA125 levels and that both natural and
stimulated ovarian cycles showed similar changing patterns. The results from
the natural group agreed with the literature in that the highest CA125 levels
were found during menstruation (Bon et al., 1999; Haga et al., 1986; Jager et al.,
1988; McLemore et al., 2012; Pittaway & Fayez, 1987; Touitou et al., 1989).The
stimulated group results also agreed with the literature where the highest
CA125 levels were found in the luteal phase of the cycle (Zweers et al., 1990). It
was suggested that CA125 levels were negatively correlated to oestradiol levels
however the lack of difference between stimulated and natural cycles suggests
that even with grossly elevated oestradiol levels, there is no significant
difference in CA125 concentrations. This would also confirm reports that it is in
fact the endometrium that is responsible for the cyclical changes in CA125
concentrations and it is the disruption of the endometrium during menses that
allows increased amounts of CA125 to enter the blood stream (Bon et al., 1999;
Kafali et al., 2007; Weintraub, Bischof, Tseng, Redard, & Vassilakos, 1990). It
was also proposed that pregnancy outcomes following ART treatment could be
predicted by measuring CA125 on the day of oocyte retrieval and that levels
>10IU/ml were correlated with an 86.6% positive pregnancy rate based on a
prospective study of 75 ART cycles (Tavmergen et al., 2001). Of the 8
participants in this study that had a CA125 of >10U/ml before oocyte retrieval,
only 3 of those became pregnant (37.5%) which is markedly lower than the
literature had suggested. There was also one participant who had a CA125 level
<10U/ml that did become pregnant. Although these results are interesting they
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are limited by the relatively small sample size but may warrant further
investigation.

Serum concentrations of CA15‐3 in natural menstrual cycles were not
statistically different to those found in stimulated cycles suggesting that ovarian
stimulation per se for the purposes of IVF and ICSI procedures does not affect
circulating serum CA15‐3 levels. The CA15‐3 concentration did however show
some interaction with the phases of the cycles which is in agreement with the
literature (Erbagci, Yilmaz, & Kutlar, 1999). The MUC1 gene, which encodes the
CA15‐3 glycoprotein, is expressed in the upper female reproductive tract and its
function has been suggested to be to prevent ectopic embryo implantation (Al‐
Azemi et al., 2009). Other studies have shown that MUC1 expression is
progesterone dependent whereby it is up regulated in the luteal phase of the
menstrual cycle (Aplin, Hey, & Graham, 1998; Hey, Graham, Seif, & Aplin, 1994).
These findings are fitting because if MUC1 is up regulated by progesterone in
the luteal phase, it would suggest that it is indeed a part of the body’s
mechanisms to avoid ectopic pregnancy. This current study has shown that
serum concentrations of CA15‐3 are at their highest in the mid‐follicular phase
of the natural menstrual cycle, which is at a time that progesterone is at its
lowest levels, suggesting that although CA15‐3 is encoded by the MUC1 gene, it
does not appear to be progesterone dependent. This being said, the previous
research on MUC1 expression was carried out on tissue samples whereas this is
an analysis of serum concentrations so the ‘lag’ in peak CA15‐3 concentrations
may not reflect activity at a local level.

Prostate specific antigen (PSA) was thought to be produced exclusively by
prostatic tissue and was therefore used to monitor prostate cancer
(Armbruster, 1993). However, it has been associated with a number of tissues
and biological events in women (EP Diamandis & H Yu, 1995) such as in the
breast (He Yu et al., 1996) and during the ovarian cycle (Aksoy, Akçay, Umudum,
Yildirim, & Memisogullari, 2002; N. Zarghami, L. Grass, E. R. Sauter, & E. P.
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Diamandis, 1997). Total prostate‐specific antigen was detectable in 60% of
women in natural cycles and 91% of women during stimulated ovarian cycles.
The range of mean results from each phase was between 0.004ng/ml –
0.012ng/ml for both natural and stimulated ovarian cycles. There was no
significant relationship between tPSA concentration and phase of the cycle, nor
was there any significant difference between tPSA concentrations in natural and
stimulated cycles. Zarghami et al., (1997) indicated that tPSA in the menstrual
cycle followed the progesterone concentration peak with a 10‐12 day delay
which was suggestive that tPSA changed in a cyclical manner. This present
study shows that tPSA concentrations were highest in the early follicular and
late luteal phase which is relative to menstruation although this did not reach
statistical significance. Total prostate specific antigen concentrations are very
low in female serum and it is not known why some women have measurable
levels of tPSA and others do not. The physiological function of tPSA in females is
yet to be determined.

Ohuchi et al. (1989) described CA72‐4 as a useful tumour marker for all
tumours derived from epithelial cells highlighting the tumour markers
increased sensitivity to gastric carcinoma compared to other tumour markers
such as CA19‐9, CEA and CA125. It was also proposed that when CA72‐4 is used
as a complimentary biomarker to CA125, the sensitivity for detecting early stage
ovarian cancer increased from 45% to 70% (Skates et al., 2004). The CA72‐4
assay used in this research failed to register any results above the assays lower
limit of detection in 40‐45.5% of individuals from both natural and stimulated
ovarian cycles. Of those individuals that did have detectable levels of CA72‐4,
the results showed an extremely high degree of variability both within each
individual (whereby each sample from the same cycle was vastly different to the
others) and between patients where the difference was so large that there were
no obvious patterns of change. It was for these reasons that statistical analysis
was not carried out and it was concluded that the assay was too unreliable for
use as a diagnostic measure in the clinical setting.
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Similar to the misnomer with PSA, the name pregnancy‐associated plasma
protein‐A (PAPP‐A) does not necessarily mean this protein is associated only
with pregnancy. Although most of the research surrounding PAPP‐A has been
performed during pregnancy (D'Antonio et al., 2013; Dane et al., 2013;
Folkersen et al., 1981; Jacobs et al., 1990; Lin et al., 1974; NJ Wald, Hackshaw,
Diamandis, & Melegos, 1999; Yovich et al., 1986), there are recent studies which
indicate differences in PAPP‐A concentrations during ART treatment cycles
(bAmor et al., 2009; Maymon & Shulman, 2002b; Orlandi et al., 2002; Tul &
Novak‐Antolic, 2006). This present study found a significant difference in the
mean concentration of PAPP‐A between natural and stimulated ovarian cycles,
where stimulated ovarian cycles were on average 2.41±0.58mIU/L lower than
natural cycles. The present study also showed that throughout each of the two
types of cycles there were no significant changes in PAPP‐A levels. Findings of
lower serum PAPP‐A concentrations in women during stimulated ovarian cycles
confirms previous work where it was shown that women had lower serum
PAPP‐A levels with higher oocyte number after oocyte retrieval, leading to the
proposal that differences in PAPP‐A concentrations may be due to the presence
of multiple corpora lutea in the ovaries (Tul & Novak‐Antolic, 2006). Amor, et al.
(2009) found that PAPP‐A levels were reduced in both fresh and frozen‐thawed
embryo transfers when compared to naturally conceived pregnancies, however,
fresh transfers did have significantly lower PAPP‐A levels than frozen‐thawed
transfers. This again provides evidence for the multiple corpora lutea theory
where the ovaries in frozen‐thawed embryo transfer cycles are not
hyperstimulated to create multiple follicle development like those of fresh
cycles. Similar to the literature which states that PAPP‐A concentrations are
similar between ART subtypes, this present study also found that there was no
significant difference between the PAPP‐A concentrations in IVF versus ICSI
cycles.

4.3 Early Pregnancy
All fourteen of the pregnancies included in this study resulted in a live birth
with no complications. The reproductive hormone levels in all individuals
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followed the classical pattern of change throughout early pregnancy, confirming
that the modelling used to express the results according to the timing of
gestation was appropriate. The progesterone levels were maintained at a
constant level via the administration of progesterone pessaries which aid in the
support of the pregnancy.

There have been many publications (Aslam et al., 2000; Halila et al., 1986;
Kobayashi et al., 1993; Niloff et al., 1984; Pittaway & Fayez, 1987) where CA125
has been measured and found to increase during pregnancy; however most of
these are reports from cross sectional studies that compare single CA125
measurements from each of the gestational trimesters. This study was different
in that serial blood samples were collected from the same women from 4 weeks
gestation through until seven weeks gestation. As the women in this study all
fell pregnant following ART treatment, important events such as ovulation were
known and implantation could be inferred from this timing. Pregnancy tests are
done fourteen days after ovulation is confirmed, which is also referred to in
obstetrics as 4 weeks gestation relative to the last menstrual period. This study
found that in early pregnancy CA125 levels were generally lower than the
clinical cut‐off value at week 4, however they did increase significantly on
average at week 5.5 before reducing again back to the normal range by week 7.
It was observed that although the statistical mean for peak concentrations was
week 5.5, there was a degree of variation on the time of gestation that these
peak levels did actually occur. It showed that there were two time points,
namely week 5 and 6.5 that had more individuals have their peak CA125
concentration. This being said, although different women had different timing
for elevated CA125 concentrations, when the data was standardised so that all
concentration peaks were labelled as t=0 and the other samples were timed
accordingly, the same significant changes in CA125 concentrations were seen.
This elevation of CA125 is concurrent with placentation events occurring in the
endometrium and along with previous suggestions that circulating CA125 is
attributable to endometrium disruption during menses, it would suggest again
that it is the disruption of the endometrium during placentation that may be
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responsible for this elevation. There have been other studies suggesting that
pregnancies with elevated CA125 (>65U/ml) in the first trimester were at an
increased risk of spontaneous abortion however in successful pregnancies the
CA125 reduced to <93U/ml between weeks 7‐12 gestation, although those
pregnancies which did abort still had levels >120U/ml (Azogui et al., 1996; Ocer
et al., 1992). The current study had four pregnant participants that had peak
CA125 levels between 94‐341U/ml where all pregnancies resulted in a live
birth. Of these four pregnancies with elevated CA125, all but one reduced to
<93U/ml by week 7, however the one participant whose CA125 did not reach
<93U/ml had her last sample collected at week 6.5 gestation so it is not known
if this would have reduced further or not. The results in this study do seem to
follow the trends highlighted in previous work and would agree with the
argument that as a predictor of spontaneous abortion, an elevated CA125 level
is an indicator of the decidual destruction which is associated with pregnancy
outcome (Ocer et al., 1992).

During early pregnancy there was a significant effect of the stage of gestation on
CA15‐3 concentrations, where the CA15‐3 concentrations declined as the
pregnancy progressed to week 7. Other studies reported in the literature have
used cross‐sectional samples collected later in pregnancy, and have shown
CA15‐3 to increase towards delivery, being higher in the third trimester than
first and second trimesters using (Bon et al., 2001; Correale et al., 1993).
Research by Meseguer et al. (2001) found that the MUC1 gene which encodes
CA15‐3 is an anti‐adhesive molecule that is expressed on endometrial epithelial
cells and the human blastocyst. The study also found that there was an increase
in the MUC1 expression during the apposition phase of implantation followed
by a localised down regulation of MUC1 during adhesion at the site of
implantation. In the present study, serum concentrations of CA15‐3 decrease
from week four to week seven of gestation which is suggestive that the declining
serum concentrations of CA15‐3 might be a potential biomarker of certain
implantation events and warrants further investigation.
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Prostate specific antigen was detectable in 9/14 (64%) of the pregnant women
in this study. In these women, PSA on average increased steadily from week 4
through week 7 of gestation where concentrations effectively doubled. There
have not been any studies that indicate the behaviour of PSA this early in
pregnancy however other literature does confirm that PSA in amniotic fluid
increased from weeks 11 to 21 and thereafter declined until birth (H. Yu et al.,
1995). Prostate specific antigen is expressed by normal, hyperplastic and
neoplastic female breast tissue so it was of interest to measure PSA in women
during early pregnancy when breast changes can occur. The PSA was seen to
increase significantly in some women whilst the breast tumour marker CA15‐3
when measured in the same women decreased. It would then appear that the
PSA circulating in the serum is not of the same origin as CA15‐3, and the role of
PSA as a marker of normal embryo implantation and development warrants
further study.

With increasing numbers of pregnancies being achieved through ART and much
research into the risks associated with a pregnancy achieved from ART, there
have been many reports that PAPP‐A levels at the first trimester screening are
reduced compared to those conceived naturally. As PAPP‐A is measured as part
of the Down syndrome screening tests, an increase in the false positive rate
would mean an increase in the number of unnecessary amniocentesis
procedures being carried out on these already precious pregnancies. The
present study measured PAPP‐A levels during the first vital weeks of pregnancy
until week seven of gestation with the intention of giving insight into the
behaviour of PAPP‐A during this time period. It was found that PAPP‐A
concentrations

increased

steadily

from

6.51±0.56mIU/ml

to125.38±22.11mIU/ml by week 7, where levels at week four were similar to
those found throughout the stimulated ovarian cycles. These pregnancies were
all conceived following ART treatment which would explain the similar PAPP‐A
levels at week four of gestation.
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Although described as a useful biomarker of various different conditions
(Ohuchi et al., 1989), CA72‐4 concentrations in this population of women were
extremely variable. The results in the group of pregnant women showed a high
degree of variability within each of the individuals however there were no
obvious patterns of change. Close to half (43%) of the women in this study did
not have detectable levels of CA72‐4, where the lower limit of detection is
<0.2U/ml. It was for this reason that statistical analysis was not carried out and
the assay was deemed too unreliable for use in the clinical setting.

4.4 Crossing of Clinical Thresholds
Whilst many biomarkers may be associated with the underlying process of a
disease, there can be many ways in which the use of the biomarker may have
limited clinical utility (Palmer & Barnhart, 2013). This can be seen with
biomarkers that were once used routinely in diagnostic medicine and originally
thought to be specific to particular diseases, but have subsequently been shown
to either (a) have a limited response in some individuals despite the presence of
the disease or (b) be associated with other biological processes and possibly
cloud the interpretation. A good example of the former is tPSA and prostate
cancer where the measurement of PSA was once recommended as a screening
test for the disease, but the recommendation has been withdrawn after studies
later highlighted that the disease can be present even when serum
concentrations of tPSA are not elevated (Thompson et al., 2004). The current
study measured a variety of biomarkers in disease‐free women during different
stages of reproductive activity, and was then able to comment upon the
possibility that the biomarkers may cross erroneously clinical thresholds,
because of other biological processes rather than the presence of the disease
itself. Although there were changes in concentrations for most of the
biomarkers, it was only CA125 during early pregnancy that consistently crossed
the cut‐off associated with disease and may have significant clinical
implications. The clinical cut‐off for CA125 as recommended by the assay
manufacturer is 35U/ml where it is said that concentrations greater than
35U/ml are associated with ovarian cancer and other gynaecological and
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inflammatory conditions. This study showed that CA125 concentrations in early
pregnancy peak between 5 and 6.5 weeks gestation (Appendix 11) and that the
maximum concentrations often exceed the clinical cut‐off for many women
(Appendix 12). These pregnancies all resulted in a live birth so it can be inferred
that a transient elevation in CA125 is not associated with adverse pregnancy
outcomes.

4.5 Summary
4.5.1

Findings

This study made evident the importance of conducting a batch analysis of all
samples from each of the participants to make certain that any changes seen
in biomarker concentrations was due to biological fluctuation and not
because of the increased batch to batch variation that is associated with some
assays. This study provided useful information about the precision of the
assays and highlighted weaknesses in some such as CA72‐4 and tPSA,
particularly at low concentrations.

Ovarian stimulation appeared to affect serum PAPP‐A levels which may
extent into pregnancy, with the IVF/ICSI cycles having significantly lower
concentrations, whilst CA125 and CA15‐3 were unaffected by ovarian
stimulation per se but showed cyclical changes throughout both the natural
and stimulated cycles. tPSA and CA72‐4 showed no consistent changes in
either natural or stimulated cycles. PAPP‐A, CA125, tPSA and CA15‐3 (but not
CA72‐4) all showed consistent but different patterns of change in early
pregnancy.

4.5.2 Implications
The biomarkers studied provided additional information over and above the
reproductive hormones in monitoring the biological events of ovarian cycles
and early pregnancy. In pregnancy, PAPP‐A, CA125, PSA and CA15‐3 are
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useful in combination for assessing different aspects of implantation,
embryogenesis and placentation. Care should be taken when interpreting
CA125 as a screen for gynaecological disease during early pregnancy as
transient elevations during this time are normal.

4.5.3 Limitations
Although participant numbers were not large (n=35) the number of serum
samples (n=223) were adequate to provide statistically significant data at all
levels of the study and to reveal consistent patterns. A limited number of
biomarkers were measured, and the additional value of others cannot be
excluded. All patients showed normal responses in terms of ovulation and
implantation, and the value of these biomarkers in disordered ovulation or
pregnancy failure cannot be commented upon.

4.5.4

Future Research

The value of additional biomarkers that can be measured using automated
assays should be investigated. The biomarkers of the current study should
also be applied to patients showing disordered ovulation or having
pregnancies with non‐viable outcomes such as ectopic implantation, blighted
ovum and spontaneous abortion.
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RESEARCH PROJECT
INFORMATION
This research project is being conducted by Melissa Stemp as part of the
requirements of a Masters Degree (MSc) at Edith Cowan University.
The title for this student research project is:

Tumour markers: concentrations in the serum of healthy women during
natural and stimulated ovarian cycles, and during early pregnancy
Every healthy person carries low levels of what are known as disease markers. When diseases occur,
the level of a particular marker may increase and therefore help with diagnosis (and monitoring) of the
disease. But we do not know whether and how hormonal changes in various stages of the reproductive
cycle may influence the level of these disease markers.

We are inviting you to participate in this study because we are looking for samples
from perfectly healthy women.
Aim of the project
a) Measure selected blood tumour markers in women, namely prostate specific antigen (PSA),
CA15-3, CA72-4, and CA125.
b) Measure these compounds in healthy women during the natural menstrual cycle, stimulated
ovarian cycle and early pregnancy.
c) Determine if the markers fluctuate or are stable, and identify possible changes in these
compounds that are a normal part of ovulation and pregnancy.
d) Measure other markers if they become available during the course of the present study, for the
same reasons.

How can you help?
Once your blood samples have had hormones measured in the normal way, we would like to use the
remainder of the samples in the project rather than it being discarded.

How will the sample be used?
The laboratory at Fertility North will measure levels of the various tumour markers in your blood.

Will these tests tell me if I have cancer?
No, you have been selected because you are healthy. Results can only be interpreted accurately for
women at risk of the disease if we understand what happens to these markers in normal women.

Will I get to see the results?
If you agree for your samples to be used then we shall send you a copy of the final report of the project.

Will the study help me?
Not directly as the results will not affect your treatment or management. However, it will hopefully
enable us to understand the dynamics of these tumour markers, which will help others.

Who will see the results of my sample?
The sample will be coded so that your identity will only be known to the staff at Fertility North.

What if I do not want my sample to be used?
You are free to refuse for your samples to be used. This will not prejudice your treatment in any way.

Who should I ask if there are any questions?
Dr Phillip Matson (Scientific Director), Dr Vince Chapple (Medical Director), Melissa Stemp
(Biochemist) and Dr Angus Stewart (senior Lecturer ECU) are the people involved in the project. These,
or any of the laboratory staff at Fertility North, will be happy to answer any questions or queries. If you
require assistance, call Dr Matson on 9301 1075.

FNC 22.

CONSENT FOR THE USE OF BLOOD IN THE RESEARCH PROJECT
ENTITLED

Tumour markers: concentrations in the serum of healthy women during natural and stimulated
ovarian cycles, and during early pregnancy.

Name:

……………………………………………………………..

Address:

……………………………………………………………..

DOB:

……………………..

I agree for my blood samples taken in this cycle to be used in this project
 only for the markers listed in the Research Project Information document,
 for the markers listed in the Research Project Information document and any other markers as
additional tumour marker assays become available during the course of this study
I also understand that:
a) Refusal would not have prejudiced my treatment in any way.
b) I am not required to have any extra blood samples taken other than those ordered by my doctor
for my own management.
c) I will be sent a copy of the final report of the study so that I may see how the blood samples
were used, and the conclusions made.
d) I am free to ask questions of the investigators during the study.
e) I will be given a copy of this consent form.

SIGNATURES

Volunteer: …………………………………………..

date ………………..

Witness: ……………………………………………..
(Must be FN member of staff)

date ………………..

The ethical aspects of this study have been approved by the Joondalup Health Campus Human Research Ethics
Committee and the Edith Cowan University Human Research Ethics Committee. If you have any complaints or
reservations about any ethical aspect of your participation in this research, you may contact the Joondalup
Health Campus Committee through the Executive Office – phone 9400 9404 or Edith Cowan University’s
Committee through Kim Gifkins – phone 6304 2170. Any complaint you make will be treated in confidence and
investigated, and you will be informed of the outcome.
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SOP
Effective Date:

Document Number: BC-S-590

09-Aug-13

Operation and Maintenance of the Siemens Centaur CP Analyser
FA-P-003

Purpose:
To provide Fertility North staff guidance in how to operate the Siemens Centaur CP Automated Analyser in a consistent and
compliant manner.
Associated Documents:
BC-F-451

CP Barcode Checklist

BC-F-459

CP Tube Cap Placemat
Advia Centaur CP Manual Operator’s Guide

Definitions:
FN

Fertility North

Responsibilities:
Role or Department
Laboratory Technician
Scientific Director

Responsible for:
 Ensuring that this procedure is adhered to in relation to measuring reproductive
hormones.
 Ensuring that this procedure is followed by all staff in the Biochemistry department.
 Ensuring that all results are validated and reported correctly on the appropriate Fertility
North documents.

Table of Contents:
1

Introduction ............................................................................................................................................................... 2

2

Reagent Preparation and Storage ........................................................................................................................... 2

3

Assay Procedure ...................................................................................................................................................... 3

4

Dilutions of Assays (ADVIA CENAUR CP) .............................................................................................................. 4

5

Assay Calibration ..................................................................................................................................................... 5

END OF DOCUMENT ........................................................................................................................................................ 6
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1

Introduction
1.1 Assay protocol for estradiol, luteinizing hormone, progesterone, human chorionic gonadotrophin and follicle stimulating

hormones.
1.2 Assay – Refer to the Advia Centaur CP - Immunoassay System (See Advia Centaur CP Manual Operator’s Guide).

2

Reagent Preparation and Storage
2.1 Reagents –For all Siemens Advia Centaur CP supplies a Reagent Diary is kept recording the Order No and date,

Arrival date, Batch No [same as previous or new], Expiry date, Date opened, and if/when QC reported. All reagents are
stored as per manufacturer’s instructions. The Order Number and same/new batch are also written on the box. The
date the box is opened is also recorded on the box.
2.2 To reconstitute samples, use the pipette pump with a glass volumetric pipette to deliver Reagent Water (filtered in

Biochemistry through Ibis system) from a sterile specimen container, recording on the sample the date of reconstitution
and the date of expiry.
Product
eE2
FSH
LH
PRGE
ThCG
Multi-dil 3
eE2 dil
ThCG dil
Cal 30
Cal B
Cal E
Immunoassay Plus
Cleaning Soln
Wash 1 Soln
R1/R2

Cat No
10491445
1360521
2212941
1586287
6031151
5389133
10491878
5609230
10379810
649625
4634452
370
9908593
1137199
497043

On Board/Recon Stability
672 hrs
672 hrs
672 hrs
672 hrs
672 hrs
672 hrs
672 hrs
672 hrs
14 days
28 days
14 days
na
na
na
na

Storage Temp
2-8 degrees
2-8 degrees
2-8 degrees
2-8 degrees
2-8 degrees
2-8 degrees
2-8 degrees
2-8 degrees
2-8 degrees
2-8 degrees
2-8 degrees
2-25 degrees
2-25 degrees
2-25 degrees
2-25 degrees

Volume to Add
Na
Na
Na
Na
Na
Na
Na
Na
2ml
5ml
2ml
5ml
Na
Na
Na
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3

Assay Procedure
3.1 Preparing the Advia Centaur CP for operation

a) Check on board supplies: - Water, Wash 1, R1/R2, primary/secondary reagents and cuvettes. [These should
have been replenished at the end of the last run]
b) Check that waste bin is empty. [This should have been done at the end of the last run]
c) Perform the Aspirate Probe Bubble Detector Calibration [Maintenance, Aspirate Probe Bubble Detector
Calibration, and Perform]
d) Perform the Automated System Prime [Maintenance, Automated System Prime, and Perform] and Close to
initialise to Ready Mode.
e) Load Quality Control Ligands, a Patient Repeat from the previous day and any calibrator tubes required.
Ligands are reconstituted to 5 mls and 7 x 600ul lots are aliquotted and available for the next 7 days. If
calibrations are due, 500ul from the appropriate reconstituted bottle is put into labelled tubes after ensuring it
is within its expiry date.
f) Perform any calibrations due by selecting the reagent tray, selecting reagent due for calibration and selecting
calibrate. [See3.9 Advia Centaur CP Manual Operator’s Guide]
g) When this is underway the Ligands and a Patient Repeat from the previous day can have their tests assigned.
To assign tests, select the sample tray and when the sample is highlighted, add each test. If the sample is
urgent it can jump the queue by also activating the stat button which shows as orange. If dilutions are
required, the dilutions button is selected and then the test and the dilution/s. Close the window and if no other
tests are running you will also need to start CP operation by selecting the start button.
h) Once calibrations and controls have been run and accepted [see 1.01.21] patient samples can be loaded as
they become available and tests assigned.

3.2 Preparation and completion of a Daily Worksheet

a) Open PowerTerm, and select D- Biochemistry menu.
b) Select A-New Worksheet, and ESC to accept the worksheet number and date.
c) Select F2, enter the date of birth, and select the matching patient.
d) Assign the sample number using the barcode reader unless it is unavailable in which case the number can be
entered manually.
e) Select F3 and using arrows to find test Select F4 to assign. Unless samples are going into patient history
rather than a cycle [assigned by nurses] the daily reference must accompany the sample. [F5 is used for this].
Fertility North documentation is considered PROPRIETARY and is made available for business operations and review by
Employees of Fertility North and Regulatory Agencies. Distribution to third parties without written permission is prohibited.
BC-S-590:01

Effective Date: 09-Aug-13

Page 3 of 6

Document number:
Effective Date:

BC-S-590
09-Aug-13

Operation and Maintenance of the Siemens Centaur CP Analyser
f) Once the samples are entered, hit F1 to go back to the menu. The Biochemistry worksheet is saved.
g) Results are manually entered from the Advia Centaur CP output - Results, Print, Today’s Records,
Consolidated Results and OK.
h) Results are transferred into PowerTerm by selecting C-Worksheet Double Entry from the Biochemistry menu
and entering each result twice.
i) Once complete, the worksheet is printed by choosing D-Worksheet Result List and cross-checked against the
Advia Centaur CP.
j) When Biochemistry staff have completed and checked results, they must validate the worksheet, making it
available for viewing and comment by Clinicians and nursing staff. To validate the worksheet choose ABiochemistry Worksheet, ensuring the correct sheet is chosen by number (there may be more than one) then
choose F2 to validate and Y to confirm.
k) Sign validation form and file with complete set of day’s paperwork including all result printouts from the CP
and completed worksheets from Powerterm.

4

Dilutions of Assays (ADVIA CENAUR CP)
4.1 Estradiol

Samples >11000 pmol/L will be automatically diluted by the Advia Centaur CP. If high or unpredictable levels are
expected samples can be pre programmed for selected dilutions when assigning the test. (See 2.42 Advia Centaur CP
Operator's Guide).

4.2 Progesterone

Samples >150 nmol/L will be automatically diluted by the Advia Centaur CP. Some luteal phase and pregnant patients
may have higher levels and if high or unpredictable levels are expected samples can be pre programmed for selected
dilutions when assigning the test. (See 2.42 Advia Centaur CP Operator's Guide)
As a guide, levels remain fairly constant throughout early pregnancy but vary between patients. Assume level will be
similar to the last sample. If borderline, leave to run neat as the test is a short one and the repeat does not result in
excessive delays.
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4.3 LH (Luteinizing Hormone)

Samples greater than 150 IU/L do not need to be diluted and should just be quoted as such.

4.4 FSH (Follicle Stimulating Hormone)

Samples greater than 110 IU/L do not need to be diluted and should just be quoted as such.

4.5 ThCG (Total Human Chorionic Gonadotrophin)

Samples >1000 IU/L will be automatically diluted by the Advia Centaur CP. Only samples of patients who are pregnant
will have continually escalating levels and will need to be diluted. Samples can be pre programmed for selected
dilutions when assigning the test. (See 2.42 Advia Centaur CP Operator's Guide)
As a guide, if the previous result was <500, then run neat; if >500 then run at 1/100; and if >50000 then run at 1/200.

5

Assay Calibration
5.1 For estradiol, luteinizing hormone, progesterone, human chorionic gonadotrophin and follicle stimulating hormones.
5.2 Frequency of calibration [see 3.9 Advia Centaur CP Operator’s Guide)

a)

LH, Progesterone and ThCG – Monthly

b)

Estradiol and FSH – 14 days

c)

When new reagent and calibration lots are introduced.

d)

Upon poor QC performance

5.3 Application of Calibrators

a)

LH, FSH, ThCG – Cal B

b)

Progesterone – Cal E

c)

Estradiol – Cal 30

The bottles specify the amount of water to add. When this is done the reconstitution and expiry dates are written on the
bottle.
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5.4 Calibration of Assays (see3.11-17 Advia Centaur CP Operator’s Guide)

a)

Prior to calibration check assay and calibration lot numbers: Scan new assay master curve barcodes if
required. Try and ensure that the calibrator has been reconstituted at least a day prior to use and at the other
extreme, that it is not expired.

b)

Prior to daily assay runs, perform any calibrations due by selecting reagent tray, selecting reagent due for
calibration and selecting calibrate.

END OF DOCUMENT
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SOP
Effective Date:

Document Number: BC-S-542

09-Aug-13

Operation and Maintenance of the Roche COBAS e411 Analyser
Purpose:
To provide Fertility North staff guidance in how to operate the Roche Cobas e411 Automated Analyser in a consistent and
compliant manner.
Associated Documents:
BC-F-410

Screening Tests Schedule

BC-F-411

Screening Results Worksheet
Roche Cobas e411 analyser operators manual

Definitions:
Fertility North

FN
Responsibilities:
Role or Department

Responsible for:

Laboratory Technician

Ensuring that this procedure is adhered to in relation to screening bloods.

Scientific Director

Ensuring that this procedure is followed by all staff in the Biochemistry department.
Ensuring that all results are validated and reported correctly on the appropriate Fertility
North documents.

Table of Contents:
1

Start-up / Pre-routine Operation Procedures ............................................................................................................... 2

1.1.6 Open lids and check for surface bubbles. If present, aspirate gently with a plastic pipette. .......................... 2
2

Routine Operation ............................................................................................................................................................. 4

END OF DOCUMENT ................................................................................................................................................................. 8
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1

Start-up / Pre-routine Operation Procedures
1.1 Preparing the Roche Cobas e411 for Operation
1.1.1 Perform a visible inspection of the machine, noting all surfaces are clean and free from debris, probes and
microbead mixer paddle are in good condition and not bent, no tubing is pinched or bent, and pipette syringes
and associated tubing are free of bubbles and not leaking system water. If these fail inspection, then remedy by
cleaning or calling the Roche Support Service.
1.1.2 Ensure that printer is switched on and contains paper.
1.1.3 With the analyser in Standby mode, top up system water with a 100+1 solution of SysWash in deionised water
(10ml: 1L).
1.1.4 Empty liquid waste container and rinse with water, and empty solid waste tray. Ensure safety glasses and gloves
are worn when emptying biohazard material.
1.1.5 Allow reagent packs to warm to room temperature and then load on to the reagent rotor the reagent packs for the
tests to be run that day. The rotor is temperature controlled to 20°C.
1.1.6 Open lids and check for surface bubbles. If present, aspirate gently with a plastic pipette.

1.1.7 Check the reagents (ProCell and CleanCell bottle sets) and consumables (AssayCup and AssayTip trays), and
ensure sufficient are on board. Top up as required, ensuring that new lots of reagents are calibrated, and the
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ProCell and CleanCell are added in pairs. The chambers holding the ProCell and CleanCell are kept to a
temperature of 28.0°C, and so reagents must be allowed 15 minutes to achieve this working temperature.
1.1.8 Open the ProCell and CleanCell lids.

1.1.9 From the home screen select the button to run a Reagent Scan. The reagent scan will check how many
AssayTips and AssayCups are onboard as well as the ProCell and CleanCell levels. It also scans the barcodes
on any reagent packs that are on board the analyser. The analyser will register any new lots and determine if the
new kits requires a calibration before it will allow it to be run.
1.1.10 The analyser is now ready for use.
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2

Routine Operation
1.1 Instrument Calibration / Quality Control

2.1.1 Calibrations should be performed at the frequency summarised in Table 2.1 and indicated below for the individual
assays. Expired calibrators should not be used and should be discarded.

2.1.2 Calibrator details are entered using the calibrator barcode card which is inserted in the barcode reader to the left
of the reagent rotor.

2.1.3 If using Position Assignment to indicate the Calibrators, then ensure that the barcode on the tube is not visible to
the scanner and that the lot number of the Calibrator is assigned to the correct positions. This is done at
Workplace>Calibration>Calibrator>Position Assignment. Select the Calibrator lot on the left of the screen, and the
rack position on the right of the screen, and choose Assign. If a previous Lot is in the rack positions then these
will need to be removed first.
2.1.4 Check if a Calibration or QC is requested by the system (Overview Screen > Calib/QC Load List)
2.1.5 Check if calibration renewal is due on each of the reagent packs. If manual calibrations are required select these
from the Calibration menu > Status > Highlight test > Select Full > Save.
2.1.6 Running the Calibrations is simply a case of placing the Calibrators in the correct rack position in the front tray
and pressing Start. Ensure that the Calibration was successful before running QCs and samples.
2.1.7 Request non-Roche controls from the QC menu > Status Highlight Control > Select > Save.
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2.1.8 Prepare calibrator and control materials i.e. reconstitute lyophilized material or thaw frozen material. Always refer
to the specific calibrator or control package insert for details.
2.1.9 Load required controls using the designated Control racks. When loading controls, ensure both levels of the same
control are next to each other on the rack with level 1 in the position in front of level 2.
2.1.10 Start measuring controls (Start > Start).
2.1.11 Once sampling is complete, remove calibrators and controls from the racks, promptly close the lids and return
them to the refrigerator.
2.1.12 Validate Calibration and Control results. Write into Endocrinology or Serology workbook and file the printed copy
under Roche Daily QC & Calibration Printouts.
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1.2 Sample Processing
2.2.1 Remove samples from the fridge and allow them to warm to room temperature.
2.2.2 Using sample racks held on a metal tray, samples are added to each rack with their barcode visible through the
rack opening, as listed in the tests schedule (BC-F-410) which defines which position each patient sample is in.
2.2.3 Once all the racks are loaded on the tray, the tray is placed in to the front compartment (A-line) of the analyser,
ensuring there is a tray on the back area, C-line, to receive the racks.
2.2.4 Press Start so that the samples pass through bar code reader.
2.2.5 Choose Workplace>Data Review and select the first tube that was read.
2.2.6 Program the patient samples by pressing Workplace > Test Selection.
2.2.7 Select the Routine option from the Sample area on the top left of the screen. A sequence number is assigned
automatically.
2.2.8 Select the Normal or Reduced option for Sample Cup.
2.2.9 Select the required dilution, if any.
2.2.10 Select the tests for the sample on the test key matrix. Once selected the test appears white.
2.2.11 Choose Save to complete the test selection.
2.2.12 Once done, bring the tray forward from the C-line back to the A-line, and replace a tray in the C-line.
2.2.13 Press Start > Start to run the samples for sampling and analysis.
2.2.14 Track sample processing by selecting Sample Tracking from the Overview screen.

Fertility North documentation is considered PROPRIETARY and is made available for business operations and review by
Employees of Fertility North and Regulatory Agencies. Distribution to third parties without written permission is prohibited.
BC-S-542:01

Effective Date: 09-Aug-13

Page 6 of 8

Document number:
Effective Date:

BC-S-542
09-Aug-13

Operation and Maintenance of the Roche COBAS e411 Analyser
1.3 Result Evaluation
2.3.1 Print patients result reports by choosing Workplace > Data Review. Highlight all patient samples and press Print >
Print.
2.3.2 Transcribe individual patient results onto the Screening Results Worksheet document (BC-F-411). This sheet will
have the matching patient barcode that is on the sample tube and the Screening Test Schedule (BC-F-410) at the
header of the patient’s results column.
2.3.3 The assay scientist validates the results written onto the Screening Results Worksheet from the hard copy that
has been printed off the Roche Cobas e411 Analyser.
2.3.4 A secondary scientist that did not run the assays then co-validates the results written onto the Screening Results
Worksheet from the original hard copy that was printed off the Roche Cobas e411 Analyser.
2.3.5 After the results have been validated by both scientists, the results are transcribed into the appropriate word
documents; “Serology Female Master” or “Serology Male Master” or “Endocrinology Female Master” or
“Endocrinology Male Master”.
2.3.6 A copy of each individual patients report is saved as Surname, Initial and the date of processing.
2.3.7 The report is copied and pasted into a new template in the patients file on Genie. The appropriate template can
be found under the Lab Reports heading. Once the template is complete and all patient details are checked and
correct the document is saved to the patients file.
2.3.8 A copy of the report is printed from the patients overview screen and is paired with the original results print out
from the Roche Cobas e411 Analyser and the Screening Results Worksheet. These are sent to the Scientific
Director for final validation.

1.4 Result Final Validation
2.4.1 The Scientific Director, or his nominated deputy, is to give the final validation of all screening results by viewing
the patient’s final report generated through the Genie program and validating that the result is the same as what
was originally printed off the Roche Cobas e411 Analyser.
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Operation and Maintenance of the Roche COBAS e411 Analyser
1.5 End of Operation / Daily Maintenance
2.5.1 Once the analyser has gone back into Standby mode you are then able to open the reagent rotor lid and press
down on the reagent caps to snap them shut. Remove all reagent packs and store in the refrigerator. Replace
rotor lid and lock.
2.5.2 Replace AssayTip and AssayCup trays that are empty.
2.5.3 Empty solid waste container and liquid waste containers ensuring safety glasses and gloves are worn to avoid
contact with hazardous material.
2.5.4 Clean the sample/reagent probe with alcohol swabs daily and check for condensation inside compartments.
2.5.5 Close the ProCell and CleanCell lids to prevent evaporation.
2.5.6 Perform any other scheduled maintenance e.g. weekly or monthly maintenance.
o

Weekly. Clean the sipper probe to prevent contamination and carryover. In addition, spills on the
incubator may cause gripper movement alarms, and so the incubator and aspiration station should be
cleaned. Empty the system water container irrespective of the amount contained and rinse with water,
then refill with 1+100 diluted SysWash.

o

Fortnightly. Clean the rinse stations for the sample/reagent probe and microbead mixer, plus the one
for the sipper probe. Liquid flow cleaning should be performed in the correct sequence to keep the
sipper liquid flow clean and maintain the integrity of the measuring cell.

o

Bimonthly. Replace the pinch valve tubing every two months.

o

As needed. Clean the liquid waste container and the microbead mixer. Also, clean the ProCell and
CleanCell compartments. Clean the reagent rotor and compartment.

o

Ensure the Cobas e411 analyser maintenance log is completed.

END OF DOCUMENT

Fertility North documentation is considered PROPRIETARY and is made available for business operations and review by
Employees of Fertility North and Regulatory Agencies. Distribution to third parties without written permission is prohibited.
BC-S-542:01

Effective Date: 09-Aug-13

Page 8 of 8

Appendix 5 – Siemens Reagent Stabilities
On Board/Recon

Storage Temp

Volume

Product

Cat No

eE2

10491445

672 hrs

2‐8 degrees

Na

FSH

1360521

672 hrs

2‐8 degrees

Na

LH

2212941

672 hrs

2‐8 degrees

Na

PRGE

1586287

672 hrs

2‐8 degrees

Na

ThCG

6031151

672 hrs

2‐8 degrees

Na

Multi‐dil 3

5389133

672 hrs

2‐8 degrees

Na

eE2 dil

10491878

672 hrs

2‐8 degrees

Na

ThCG dil

5609230

672 hrs

2‐8 degrees

Na

Cal 30

10379810

14 days

2‐8 degrees

2ml

Cal B

649625

28 days

2‐8 degrees

5ml

Cal E

4634452

14 days

2‐8 degrees

2ml

370

‐

2‐25 degrees

5ml

Cleaning Soln

9908593

‐

2‐25 degrees

Na

Wash 1 Soln

1137199

‐

2‐25 degrees

Na

R1/R2

497043

‐

2‐25 degrees

Na

Immunoassay
Plus

Stability

Na = not applicable as product is supplied in liquid form.
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Appendix 6 – Roche Reagent Stabilities
Stability

Assay

Test
time

Unopened

Opened

Calibration
On‐board

2‐8°C

2‐8°C

analyser

Initial

On‐board

Stored same

analyser

lot

Measuring range

CA125 II

18 mins

Exp. Date

12 weeks

6 weeks

Within 24hrs

7 days

1 month

0.6‐5,000 U/mL

CA15‐3 II

18 mins

Exp. Date

12 weeks

5 weeks

Within 24hrs

7 days

1 month

1.00‐300 U/mL

CA72‐4

18 mins

Exp. Date

12 weeks

8 weeks

Within 24 hrs

7 days

1 month

0.200‐300 U/mL

tPSA

18 mins

Exp. Date

12 weeks

4 weeks

Within 24hrs

7 days

1 month

0.003‐100 ng/mL

PAPP‐A

18 mins

Exp. Date

4 weeks

3 weeks

Within 24 hrs

7 days

1 month

4‐10000 mIU/L
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Appendix 7 – Roche QC Material
Assay

CA125,
CA15‐3,
CA72‐4,
tPSA

QC material

No.
Levels

Elecsys
PreciControl

2

Tumor marker

Reconstitution Storage Stability

3 mls water
each

‐20˚C

1 month

‐20˚C

1 month

CA125,
CA15‐3,

Biorad Lyphochek

CA72‐4,

Tumor Marker Plus

3

2 mls water
each

tPSA
Elecsys
PAPP‐A

PreciControl

3

Maternal Care
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3 mls water
each

‐20 ˚C

3
months

Appendix 8 – Change in mean concentration of CA125 in ovarian
cycles, natural and stimulated combined.
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Appendix 9– Change in the mean concentration during early pregnancy
of CA125, CA15‐3 and tPSA.
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